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Preface
This thesis was prepared at the Department of Systems Biology, the Technical
University of Denmark, in partial fulﬁllment of the requirements for acquiring
the Ph.D. degree.
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SUMMARY vii
Summary
The human immune system is a highly adaptable system, defending our bod-
ies against pathogens and tumor cells. Cytotoxic T cells (CTL) are cells of
the adaptive immune system, capable of inducing a programmed cell death
and thus able to eliminate infected or tumor cells. CTLs discriminate be-
tween healthy and infected cells based on peptide fragments presented on the
cells surface. All nucleated cells present these peptide fragments in complex
with Major Histocompatibility Complex (MHC) class I molecules. Peptides
that are recognized by CTLs are called epitopes and induce the CTLs to
subsequently kill the infected cells.
The focus of my PhD project has been on improving a method for CTL
epitope pathway prediction, on analyzing the epitope density in the alter-
native cancer exome, and on a study investigating minor histocompatibility
antigens (mHags) associated with leukemia.
Part I is an introduction to the ﬁelds covered in the thesis. Part II de-
scribes a pan-speciﬁc, integrative approach for the prediction of CTL epi-
topes. The presented method, NetCTLpan, an improved and extended ver-
sion of NetCTL, performs predictions for all MHC class I molecules with
known protein sequence and allows predictions for 8, 9, 10 and 11-mer epi-
topes. One of the major beneﬁts of the method is its optimization to achieve
high speciﬁcity. Its low false positive rate is especially useful in rational
reverse immunogenetic epitope discovery approaches. When this method is
compared to the NetMHCpan and NetCTL methods, the experimental eﬀort
to identify 90% of new epitopes can be reduced by 15% and 40%, respectively.
Part III reports the results of an analysis investigating how the alterna-
tively spliced cancer exome diﬀers from the exome of normal tissue in terms
of containing predicted MHC class I binding epitopes. We show that peptides
unique to cancer splice variants comprise signiﬁcantly fewer predicted HLA
class I epitopes than peptides unique to spliced transcripts in normal tissue.
We furthermore ﬁnd that hydrophilic amino acids are signiﬁcantly enriched
in the unique carcinoma sequences, which contribute to the lower likelihood
of carcinoma-speciﬁc peptides to be predicted epitopes. Carcinoma is known
to have developed mechanisms for evading the host’s immune system. Here,
we show for the ﬁrst time that carcinoma has a bias towards fewer possible
epitopes already at the step of mRNA splicing.
Part IV of the thesis deals with the analysis of 93 patient-donor pairs
that underwent hematopoietic stem cell transplantation (HCT). HCT is a
standard treatment for a variety of hematological diseases. Graft-versus-host
disease is a possible complication after an HCT, where the recipient´s cells
are perceived as foreign and the target of an immune response mediated by
the donor´s transplanted immune cells. The immune response is provoked
by epitopes unique to the patient, so-called mHags. Here, a gene-speciﬁc
association between the number of SNPs or predicted mHags and the possible
clinical outcome following an HCT is presented.
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Dansk resumé
Det humane immunsystem er et meget tilpasningsdygtigt system, som for-
svarer vores krop mod patogener og tumorceller. Cytotoksiske T-celler (CTL)
er celler fra vores adaptive immunsystem, som er i stand til at forårsage pro-
grammeret celledød og dermed eliminere inﬁcerede celler eller tumorceller.
CTLs kan skelne mellem raske og inﬁcerede celler på baggrund af peptidfrag-
menter præsenteret på cellernes overﬂade. Alle kerneholdige celler præsente-
rer disse peptidfragmenter i kompleks med Major Histocompatibility Com-
plex (MHC) klasse I molekyler. Peptidfragmenter, der genkendes af CTLs,
kaldes epitoper og inducerer efterfølgende CTLs til at dræbe de inﬁcerede
celler.
Fokus i mit PhD projekt har været på at forbedre en metode til CTL epi-
top pathway forudsigelse, ved at analysere epitop-tætheden i det alternative
cancer exom og ved et studie af minor histocompatibility antigener (mHags)
associeret med leukæmi.
Del I er en introduktion til de områder, der bliver dækket i denne af-
handling. Del II beskriver en pan-speciﬁk integrativ tilgang til forudsigelsen
af CTL epitoper. Den præsenterede metode, NetCTLpan, en forbedret og
udvidet version af NetCTL, kan forudsige alle MHC klasse I molekyler med
kendte protein sekvenser og tillader forudsigelser for 8, 9, 10 og 11-mer epi-
toper. En af de store fordele ved denne metode er, at den er optimeret til at
opnå høj speciﬁcitet. Dens lave falsk positive rate er især brugbar i forbin-
delse med rationel omvendt immunogenetisk epitop opdagelsestilgange. Ved
at sammenligne denne metode med NetMHCpan og NetCTL metoderne kan
den eksperimentelle indsats, der er nødvendig for at identiﬁcere 90% af nye
epitoper, reduceres med henholdsvis 15% og 40%.
Del III beskriver resultaterne af en analyse, hvor det undersøges, hvordan
det alternativt splejsede cancer exom afviger fra exomet i normalt væv, i
forbindelse med indholdet af forudsagte MHC klasse I epitoper. Vi viser, at
peptider, som er unikke for cancer splejsningsvarianter, indeholder væsent-
ligt færre forudsagte HLA klasse I epitoper end peptider, der er unikke for
splejsede transkripter i normalt væv. Vi konstaterer ydermere, at hydroﬁ-
le aminosyrer er signiﬁkant beriget i de unikke karcinom sekvenser, hvilket
bidrager til den lavere sandsynlighed for at forudsige epitoper i karcinom-
speciﬁkke peptider. Karcinoma er kendt for at have udviklet mekanismer til
at undvige værtens immunsystem. Her viser vi for første gang, at karcinoma
har en bias mod færre mulige epitoper allerede ved mRNA splejsningen.
Del IV af afhandlingen beskæftiger sig med analyse af 93 patient-donor
par, der har fået foretaget en hæmatopoietisk stamcelle transplantation
(HCT). HCT er en standard behandling for en lang række hæmatologiske
sygdomme. Graft-versus-host sygdom er en mulig komplikation efter en HCT,
hvor visse af modtagerens celler opfattes som fremmede, og donorens trans-
planterede immunceller medierer et immunrespons mod dem. Immunrespon-
set er fremprovokeret af epitoper, der er unikke for patienten, såkaldte mHags.
Her præsenteres en gen-speciﬁk forbindelse mellem antallet af SNPs eller for-
udsagte mHags og mulige kliniske forløb efter en HCT.
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Chapter 1
Introduction
1.1 From DNA to protein
“Once information has got into a protein it can´t get out again”. The central
dogma of molecular biology enunciated by Francis Crick in 1958 is a frame-
work describing the sequential transfer of information from DNA to protein
[15]. Crick concluded that the ﬂow of information is from nucleic acid (DNA
or RNA) to protein. In general the dogma is covering three principles: DNA
replication, a biological process where DNA is copied; Transcription, a step
where DNA is copied to messenger RNA (mRNA); and translation, where
mRNA is decoded to amino acids and further folded into a protein. More
and more exceptions to the “Central Dogma” are described. RNA can make
copies of itself and it is possible to go back to DNA from RNA. However,
there is no known mechanism for proteins to make copies of themselves, nor
is it known to be possible to go back to DNA or RNA from proteins.
Alternative splicing
When the ﬁrst euchromatic sequence of humans was sequenced and assembled
in 2001 by Venter et al. they provided a major surprise: They found that the
number of human genes is far lower (26,000 to 38,000) than earlier molecular
predictions ranging from 50,000 to over 140,000 genes [118]. Further, it was
shown that the human genome encodes only 20,000 to 25,000 protein-coding
genes [12]. While one-third of the human genome would be transcribed as
genes, only about 1.5% of the human genome codes for proteins [50].
Compared to other organisms, the amount of genes in human is noth-
ing spectacular. We have approximately the same amount of protein-coding
genes as ﬂies and mice, the number of protein-coding genes for a round-
worm (13,000) is more than half compared to humans, and rice was found
1
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Figure 1.1. Gene transcription and translation. Double-stranded DNA
unwinds and its triplet code is transcribed to mRNA. Translation is the
process of protein synthesis, accomplished by mRNA along with ribosomes
and tRNA.
to have more than 46,000 genes [131]. These ﬁndings raised the question for
the source of organism complexity. Alternative splicing, which is the pro-
cess of inclusion or exclusion of regions of the pre-mRNA, was discovered as
one of the major mechanisms for increasing transcript diversity. It changes,
by inclusion or skipping of exons, the structure of mRNA and further their
encoded proteins. This may lead to aﬀected function, stability or binding
properties of encoded proteins.
Studies have shown that there are other, previously unknown mechanisms,
like antisense transcription, where a large proportion of the genome can pro-
duce transcripts from both strands [41]. This shows that there are diﬀerent
mechanisms for increasing genomic diversity, but alternatively splicing, which
has been shown to occur in 9̃5% of multiexonic human genes, is still found
to be a major driving force [75].
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Figure 1.2. Two DNA fragments contain a diﬀerence in a single nucleotide.
A C/T SNP is shown. (David Hall, Creative Commons License)
Single nucleotide polymorphisms
A single-nucleotide polymorphism (SNP) is a single nucleotide variation (A,
T, C or G) in the genome diﬀering between members of a species or between
homologue chromosomes within an individual. A SNP may, for example, re-
place the nucleotide cystine (C) with the nucleotide thymine (T) at a speciﬁc
position (see Figure 1.2).
Several projects are genotyping SNPs with the aim of providing public
resources for genetic research. Approximately 10 million SNPs in humans
were identiﬁed by the Human Genome Project, the SNP Consortium and the
International HapMap Project [1].
There are diﬀerent types of SNPs, depending on which location within the
DNA sequence the SNP occurs. A SNP is a non-coding SNP, if the SNP is
falling within intergenic regions or non-coding regions of genes. These SNPs
are not translated to proteins, some of them might, however, have an inﬂu-
ence on the level of gene expression, transcription factor binding or aﬀect
gene splicing. If a SNP is located within a region coding for a protein, it is
called a coding SNP. Due to the redundancy of the genetic code, some of the
nucleotides coding for amino acids can be exchanged without changing the
amino acid that the triplet codes for, not all coding polymorphisms result in
a change in the amino acid sequence of a protein. This type of SNPs, where
both alleles result in the same ﬁnal amino acid sequence, are called synony-
mous SNPs. Nonsynonymous SNPs are, on the other hand, SNPs where the
polymorphism leads to a change in the resulting protein. Nonsynonymous
SNPs can be divided into missense mutation, where translation results into a
diﬀerent amino acid, or nonsense mutation, which results in the introduction
of a stop codon and truncation of the ﬁnal protein.
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The human genome is 3-billion bases long - every 100 to 300 bases a SNP
occurs. This variation makes up 90% of all genetic variation found in humans
[50]. SNP variations are correlated to diseases and functional variations, even
allowing to assign phenotypic characteristics based on the genome sequence
of an extinct ancient human [83].
1.2 The adaptive immune system
The immune system is a protection system against infectious disease,
pathogens and tumor cells. It consists of two parts: The innate immune
system as the ﬁrst line of defense and the highly diverse, but slower, adaptive
immune system. Innate immune responses are not speciﬁc to a particular
pathogen and have no memory if encountering the same pathogen. In con-
trast, if the adaptive immune system encounters the same antigen again, the
second response will be much more rapid and stronger than the primary re-
sponse. Both systems cooperate with each other, but from the point of view
of personalized medicine and transplantation medicine, the highly specialized
adaptive immune system is a more interesting target than the innate immune
system.
The adaptive immune system is highly speciﬁc. Its antigenic speciﬁcity
allows antibodies to recognize subtle diﬀerences between proteins only dif-
fering by a single amino acid. It has further a high diversity in recognizing
billions of diﬀerent structures. Due to the immunologic memory, after an
initial encounter, it oﬀers a lifelong protections against some infectious dis-
eases. Further, because of its self-nonself recognition, the adaptive immune
system is normally capable of only reacting to foreign antigens.
Lymphocytes and antigen-presenting cells are the two major groups of
cells involved in an adaptive immune response. Lymphocytes are white blood
cells circulating in the lymphatic systems and in the blood. The two major
lymphocytic cell types are B and T lymphocytes. The main role of the B
lymphocytes, also called B cells, is the creation of antibodies for identifying
and neutralizing foreign objects. There is a huge variation in the antigen
binding site of diﬀerent B cells, enabling the immune system to detect a vast
amount of diﬀerent antigens (for example pathogens). A B cell encountering
an antigen matching its antibodies the ﬁrst time causes the cell to divide
rapidly. B cells diﬀerentiate into memory B cells plasma cells. Memory B cells
have a long lifespan and enable the immune system to react faster if the host
gets infected by the same antigen again. Further, accumulating their amount
enables a strong immune response. Plasma cells produce antibodies with
the same speciﬁcity as their parent B cells, but in a secretable form. These
secreted antibodies bind to and inactivate antigens. In humans, secreted
antibodies are the major eﬀector of the immune system, per second up to
thousands of antibodies can be secreted by a single plasma cell.
The other major group of cells, which is part of the adaptive immune
system, is the T lymphocytes. In contrast to B cells, which are able to bind
to free antigen, T lymphocyte receptors usually bind to antigen in complex
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with a major histocompatibility complex (MHC) molecule. If a T lymphocyte
encounters an antigen combined with MHC, the T lymphocyte proliferates
into various eﬀector T lymphocytes and memory T lymphocytes. One type of
eﬀector cells are cytotoxic T lymphocytes (CTL). This group of lymphocytes
is known to induce death of infected somatic cells and tumor cells. Further,
CTLs are capable of eliminating cells of a foreign tissue graft.
Cytotoxic T cells
CTLs are a key player for the eﬀector function of the adaptive immune system
[3]. Due to their ability to destroy cells posing a threat to the organism, it
is crucial that these cells are capable of distinguishing between a potential
threat and harmless cells originating from self proteins. CTLs are also known
as CD8+ T cells, since they express a CD8 co-receptor at the cell´s surface.
T cells are educated in the thymus to distinguish between self and non-
self. T lymphocytes arise in the bone marrow and subsequently migrate to
the thymus, an organ of the immune system, for maturation. The somatic
rearrangement during this process leads to the expression of a unique T cell
receptor (TCR) [3]. In 95% of all T cells. the TCR is composed by an 
and a  protein chain. Each chain is composed of diﬀerent gene segments.
Functional TCR genes are produced by rearranging variable (V) and joining
(J) gene segments for the  chain and by rearranging V, J and an additional
diversity (D) gene segments for the  chain. The rearrangement of gene
segments and a further addition of random nucleotides results in 1018 possible
combinations and therefore unique TCRs. This diversity is the key for the
detection and subsequent combating of pathogens.
This huge repertoire of potential T cells undergoes a selection process.
The selection process consists of two parts: the positive selection and the
negative selection. Positive selection ensures that a potential T cell is capable
of binding to self-MHC molecules. T cell precursors have to interact with self-
MHC molecules, cells that fail to bind are eliminated by apoptosis. Positive
selection results in MHC restriction and ensures that only T cells capable of
binding to self-MHC molecules survive.
The second selection process, negative selection, ensures that T cells are
not binding too strongly with self-MHC or self-MHC in complex with self-
peptides. Negative selection results in self-tolerance. This is crucial, as T
cells should not induce cell death to the host´s cells. A partial failing of
this mechanism is a potential cause for autoimmune diseases. A graphical
representation is shown in Figure 1.3.
Class I antigen processing
All proteins in eukaryotic cells are continuously degraded into peptide frag-
ments and most of these peptides are further degraded into their constituent
amino acids. A selection of these peptides, composed of 8-11 amino acids,
escape complete destruction and are displayed on the cell (or ‘s surface by
6 CHAPTER 1. INTRODUCTION
Figure 1.3. Positive and negative selection of potential T cells in the thy-
mus. Positive selection results in MHC restriction; negative selection results
in self-tolerance. From Kuby Immmunology [45].
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Figure 1.4. MHC class I antigen presentation pathway. Intracellular pro-
teins are degraded by the proteasome into peptides. The peptides are trans-
ported into the ER by TAP. In the ER, an immature MHC class I complex
binds to TAP; a stable peptide/MHC complex is formed with a suitable pep-
tide. This complex is transported via the Golgi apparatus to the cell surface,
where it is presented for interaction with T cells. From Andersen et al. [4]
MHC class I molecules [89]. By this mechanism, the cell is presenting its
internal world to the outside. T cells are able of recognizing the presented
complex and distinguish between self and foreign peptides.
There are three essential steps involved in the expression of a pep-
tide/MHC class I complex at the cells surface: proteasomal cleavage of pro-
teins, translocation by the transporter associated with antigen processing
(TAP) molecule to the endoplasmatic reticulum (ER), and the assembly of
the MHC with the antigenic peptide, following the transport of the the pep-
tide/MHC complex to the cell surface [4]. The antigen processing pathway
is shown in Figure 1.4.
The major protease for cutting proteins into peptides is the proteasome.
Presentation of peptides on the cell surface is decreased by as much as 90%
by proteasome inhibitors, whereas at the same time some speciﬁc peptides
are shown to increase their surface expression. This indicates that other pro-
teases are also involved in the degradation of proteins [56]. The proteasome
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is required to generate the C-terminal but not the N-terminal ends of pep-
tides presented in the context of MHC class I [63, 14]. N-terminal trimmed
peptides are transported by the TAP molecule to the ER. TAP consists of
two subunits, TAP-1 and TAP-2, forming a binding pocket. TAP preferen-
tially binds to peptides of size 10-18 amino acids. These peptides are larger
than peptides presented by MHC class I, additional trimming of the peptides
occurs at a later stage in the ER. A model for predicting TAP aﬃnity high-
lights that the C-terminal and the three outmost N-terminal amino acids are
the key residues in deﬁning binding aﬃnities to TAP [78]. Once translocated
to the ER, additional trimming of the peptides to a length of approximately
8-11 amino acids occurs. Within the ER, peptides are trimmed from the N-
terminal side mainly; C-terminal trimming in the ER was shown to occur at
a much lower frequency by several studies [103, 21]. This ineﬃciency of the
ER to trim peptides at the N-terminus supports the idea of protease being
the main workhorse for N-terminal trimming. At this step there are still a
vast amount of possible peptides to choose from for binding to MHC class
I. The binding of peptides to MHC molecules is the most stringent factor
limiting presentation of possible epitopes on the cell surface. It is estimated
that only 1 out of 200 potential peptides binds to a particular MHC class
I molecule and that only half of these are immunogenic due to limitations
in the T cell repertoire. Taking all steps of the antigen processing pathway
into account, only 1 out of 2,000 possible epitopes is able to elicit a T cell
response [129].
1.3 Hematopoietic cell transplantation
Hematopoietic stem-cell transplantation (HCT) is a standard treatment for
a variety of malignant diseases and hematological malignancies [32]. It con-
sists of an intravenous infusion of hematopoietic stem cells, with the goal of
reestablishing marrow functions in patients with defective bone marrow or
immune systems. In a report from 1939, an intravenous marrow infusion for
treating aplastic anemia is described for the ﬁrst time [74]. Over the years,
with the discovery of human leukocyte antigen (HLA) and the later use of
immunosuppressive drugs for minimizing Graft-versus-host disease (GVHD),
HCT has become an eﬀective treatment for diﬀerent diseases, applied to
thousands of patients every year.
Depending on the source of the graft, distinctions are made between two
types of HCT: If the patients own marrow is used to reestablish hematopoietic
function, it is called an autologous HCT. One of the beneﬁts of this method
is a low occurrence of GVHD, since the transplant comes from the patient
himself. For some types of hematologic diseases, however, autologous HCT
leads to lower survival than allogeneic HCT due to disease related mortality
[8]. Allogeneic HCT is the other possible approach; it involves the transfer
of marrow from another person, the donor, to a recipient. Patients undergo
an immunosuppressive therapy and the patients immune system cells are
replaced by the transplant [130]. The absence of malignant cells in the graft
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and a possible Graft-versus-tumor (GVT) eﬀect are the major advantages of
allogeneic HCT. Main disadvantages are the risk of GVHD and diﬃculties in
ﬁnding an appropriate donor [64].
Hematologic malignant diseases
Hematological malignancies are cancers of the blood, the bone marrow or
lymph nodes. The classiﬁcation of hematological malignant diseases is based
on their main occurrence: It is deﬁned as leukemia if the malignancy is mainly
located in blood, and lymphoma, if it is mainly aﬀecting the lymph nodes. A
more speciﬁc categorization including diagnostic criteria, associated genetic
alterations and pathological features, is regularly published by the World
Health Organization, currently in its 4th edition [73]. A rough classiﬁca-
tion is further possible by the cell lineage. First, there are hematological
malignancies derived from myeloid cell lines. Myeloid leukemias are further
divided into acute (AML) and chronic (CML) myelogenous leukemia. Sec-
ond, lymphoid leukemia and lymphoma is derived from lymphoid cell lines.
Lymphoma is usually a solid tumor, whereas lymphoid leukemia is aﬀecting
lymphocytic cells in the blood.
Donor selection
The selection of an appropriate donor is a major factor for the success of an
HCT. Each HLA mismatch does not only lead to a diﬀerence of the speciﬁc
HLA molecule, but also in the vast amount of peptides each HLA molecule
is able to present to T cells at the cell surface, with the possibility of leading
to a strong immune response.
While transplantation of graft from an HLA-matched sibling shows the
best results, only 30%of the patients have the possibility for such a donor
[64]. For ﬁnding an optimal donor, histocompatibility testing is done by high
resolution typing to identify diﬀerences in nucleotides for the HLA-A, -B,
-C, DRB1 and DQB1 alleles. There are 10 possible variations in a given
patient, as humans have two homologous copies of each chromosome. If all
alleles for a recipient and a donor are matching, they are deﬁned as 10/10
matched. Accordingly, a single HLA locus disparity would be a 9/10 match
and a multi-locus mismatch with two disparities would be a 8/10 match [120].
In the 1980s, national donor registries were started as a consequence of risen
demand for unrelated donors. In an eﬀort to enable international searches,
Bone Marrow Donors Worldwide started to connect national registries and
organizations [10]. Established in 1988, the database is now providing cen-
tralized access to almost 18 million donors. In recent years, availability of
these databases and advances in HLA typing have greatly improved donor
matching. A study including more than 11,000 patients reports a signiﬁcant
increase of 10/10 matched patient-donor pairs. From 1987-1998, only 28%
of donor-patient pairs had no identiﬁed HLA mismatch, whereas this was
increased to more than half from 1999-2002 and to 65% from 2003-2006 [40].
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Major Histocompatibility Complex
The major histocompatibility complex (MHC) is a gene family whose prod-
ucts are presenting intercellular products to the cell´s outside. All known
mammalian species have an MHC complex. In humans they are called hu-
man leukocyte antigens (HLAs). In humans, the MHC is organized into three
regions: Class I, II, and III. Class I type MHCs are present on the surface
of nearly all cells. They are presenting peptides from the cell´s inside to the
cell´s outside. Class II MHCs are only expressed by a subset of somatic cells.
They are mainly found on B cells, macrophages and dendritic cells. Peptides
presented by MHC class II are, in contrast to peptides presented by MHC
class I, derived from extracellular proteins. MHC class III molecules do not
share a similar function with MHC class I and II. They are located on chro-
mosome 6 between the other MHC molecules and code for immune-related
proteins.
Minor Histocompatibility Antigens
Minor histocompatibility antigens (mHags) are a possible source for the re-
jection of MHC-matched transplants [88]. Even in a perfectly MHC matched
allogeneic HCT, small variations in other proteins can cause the rejection of
a grafted tissue. First found in mice, mHags were later recognized as be-
ing additional histocompatibility loci in human by rejection of skin grafts
exchanged between HLA-identical siblings [11]. Later still, it was suggested
that typing for some mHags prior to hematopoietic cell transplantation may
identify patients at high risk for graft-versus-host disease and improve donor
selection [30]. Minor histocompatibility antigens are peptides, derived from
cellular proteins and presented at the cells surface, where they are recognized
by MHC-restricted T lymphocytes and further raise an immune response
[99]. It has been shown that both CD8+ (class I restricted T cells) and
CD4+ (MHC class II restricted T cells) respond to mHag epitopes, albeit by
diﬀerent mechanisms [91].
Graft-versus-host disease
Graft-versus-host disease (GVHD) is a complication after a hematopoietic
cell transplantation, where healthy cells of the recipient are attacked. The
recipient´s cells are seen as foreign and an immune response is mediated by
the donor´s transplanted immune cells. An HLA mismatch between donor
and recipient is a possible source for GVHD. In addition to an HLA mis-
match, mHags may raise an attack by the immune system. A one amino acid
diﬀerence in a protein presented by MHC can be enough to be perceived as
foreign by the donor´s T cells and to trigger an immune response.
GVHD is divided into acute GVHD (aGVHD) and chronic GVHD
(cGVHD). GVHD occuring within the ﬁrst 100 days after HCT is called
aGVHD, whereas the chronic form of GVHD normally occurs after 100 [29].
Tissues typically aﬀected by aGVHD are liver, skin and the gastrointestinal
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tract. By deﬁnition, each of these tissues and the overall grade of aGVHD
are divided into grades from I-IV, where no treatment is required for grade
I and grade IV is fatal [79]. Chronic GVHD is usually appearing at a later
stage than aGVHD and involves more immune related cell types. It is further
aﬀecting a broader range of tissues. The classiﬁcation system used for staging
of chronic GVHD, originally proposed by the Seattle Group and based on 20
patients, diﬀerentiates between “limited” and “extensive” [54]. Several addi-
tional classiﬁcation scales were developed allowing a ﬁner grading of patients.
However, the “limited/extensive” classiﬁcation is still the most widely used.
Graft-versus-tumor eﬀect
The graft-versus-tumor (GVT) eﬀect is a beneﬁcial eﬀect, based on the same
principles that lead to GVHD. Immunological non-identity between recipient
and donor, as induced by mHags, are responsible for GVHD, but they may
also support tumor eradication [124]. The GVT eﬀect was shown to reduce
the risk of relapse for leukemia patients following an allogeneic transplant.
Malignant target cells are recognized as foreign by the donor’s immune cells
and a response is initiated by the donor’s CTLs and natural killer cells [85].
As the GVT eﬀect is relying on the same principles as GVHD, one of the
challenges of HCT is the prevention of undesirable GVHD without loosing
the favorable GVT eﬀect. Recent studies have shown that immunotherapy
using donor lymphocytes can produce a GVT eﬀect without leading to GVHD
[47]. Several mHags exclusively expressed in hematopoietic tissues have been
described [122]. Because of their hematopoietic cell-restricted cell damage,
these mHags can be speciﬁcally used to eliminate a hematologic malignant
disease, such as leukemia. These mHags are associated with a low risk of
GVHD, as GVHD is targeting other organs such as skin or liver cells [65].
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2.1 Abstract
Reliable predictions of immunogenic peptides are essential in rational vaccine
design and can minimize the experimental eﬀort needed to identify epitopes.
In this work, we describe a pan-speciﬁc major histocompatibility complex
(MHC) class I epitope predictor, NetCTLpan. The method integrates predic-
tions of proteasomal cleavage, transporter associated with antigen processing
(TAP) transport eﬃciency, and MHC class I binding aﬃnity into a MHC
class I pathway likelihood score and is an improved and extended version of
NetCTL. The NetCTLpan method performs predictions for all MHC class
I molecules with known protein sequence and allows predictions for 8-, 9-,
10-, and 11-mer peptides. In order to meet the need for a low false positive
rate, the method is optimized to achieve high speciﬁcity. The method was
trained and validated on large datasets of experimentally identiﬁed MHC
class I ligands and cytotoxic T lymphocyte (CTL) epitopes. It has been re-
ported that MHC molecules are diﬀerentially dependent on TAP transport
and proteasomal cleavage. Here, we did not ﬁnd any consistent signs of such
MHC dependencies, and the NetCTLpan method is implemented with ﬁxed
weights for proteasomal cleavage and TAP transport for all MHC molecules.
The predictive performance of the NetCTLpan method was shown to out-
perform other state-of-the-art CTL epitope prediction methods. Our results
further conﬁrm the importance of using full-type human leukocyte antigen
restriction information when identifying MHC class I epitopes. Using the
NetCTLpan method, the experimental eﬀort to identify 90% of new epi-
topes can be reduced by 15% and 40%, respectively, when compared to the
NetMHCpan and NetCTL methods. The method and benchmark datasets
are available at http://www.cbs.dtu.dk/services/NetCTLpan/.
2.2 Introduction
Cytotoxic T lymphocytes (CTLs) are a subgroup of T cells able to induce cell
death of other cells. CTLs kill only infected or otherwise damaged cells. In
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order to discriminate between infected and healthy cells, all nucleated cells
present host cell peptide fragments on the cell surface in complex with major
histocompatibility complex class I molecules (MHC class I). Not all possible
peptides originating from cell proteins will be presented by MHC class I. In
fact, it is estimated that only one out of 2,000 potential peptides will be im-
munodominant [129]. One of the ﬁrst steps involved in MHC class I antigen
presentation is the degradation of intracellular proteins, including proteins
from the cytoplasm and nucleus, by the proteasome [52, 76, 14, 2, 63, 107, 38].
These peptides may be trimmed at the N-terminal end by cytosolic exopepti-
dases [55]. A subset of the peptides is transported by transporter associated
with antigen processing (TAP) complex into the endoplasmatic reticulum
(ER), where further N-terminal trimming occurs [87, 46, 116, 94]. Inside the
ER, a peptide may bind to an MHC class I molecule and the peptide–MHC
complex will be transported to the cell surface, where it subsequently may be
recognized by CTLs. These successive steps from protein to ligand presented
on the cell surface are limiting the number of possible epitopes. The most
restricting step in antigen presentation is peptide binding to MHC class I
molecule [129].
Reliable predictions of immunogenic peptides can minimize the experi-
mental eﬀort needed to identify epitopes. We have previously described a
method, NetCTL [52, 53], integrating MHC class I binding, TAP transport
eﬃciency, and proteasomal cleavage predictions to an overall prediction of
CTL epitopes. The NetCTL method has proven successful in identiﬁcation of
CTL epitopes from, for instance inﬂuenza [121], HIV [77], and Orthopoxvirus
[110]. Several other groups have developed methods for CTL epitope iden-
tiﬁcation by integrating steps of the MHC class I pathway (MAPPP, [31];
WAPP, [17]; EpiJen, [18]; MHC-pathway, [111]). All these methods are lim-
ited by the fact that they only allow for prediction of peptide binding to a
highly limited set of diﬀerent MHC molecules. In a large-scale benchmark
evaluation of publicly available server of MHC class I pathway presentation
prediction, Larsen et al. [52] showed that the NetCTL method signiﬁcantly
outperformed all these methods, closely followed by MHC-pathway. The
MHC-pathway method has recently been updated to include more accurate
predictions of MHC binding and a broader allelic coverage (close to 60 hu-
man leukocyte antigen (HLA)-A and HLA-B alleles are covered by the de-
fault MHC-pathway method in the 2009-09-01 release). In contrast to this,
the NetCTL method has not been updated since 2007, and the MHC binding
prediction remains limited to the 12 common HLA supertypes [57]. In the
following, we describe an improved and extended version of NetCTL, called
NetCTLpan, which is able to make predictions for all MHC class I molecules
with known protein sequence. In addition, NetCTLpan can identify 8-, 9-
, 10-, and 11-mer epitopes, as opposed to NetCTL, which only allowed for
prediction of 9-mer epitopes. The method has been trained on a large data
set of experimentally identiﬁed MHC ligands from the SYPFEITHI database
[80]).
Choosing a performance measure for evaluating a prediction method is a
nontrivial task, and the deﬁnition of performance measure will often inﬂuence
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the benchmark outcome and subsequent choice of best method. A commonly
used measure for predictive performance is the area under the receiver oper-
ating characteristic (ROC) curve, the AUC value. This measure integrates
the sensitivity curve as a function of speciﬁcity for the range of sensitivity
from one to zero. This measure might not be optimal if a prediction method
is required to have a very high speciﬁcity in order to lower the false positive
rate for subsequent experimental validation. In such situations, it could be
beneﬁcial to use only the high speciﬁcity part of the ROC curve to calculate
the predictive performance. To match such requirements for a low false pos-
itive rate, we have therefore in this work focused on optimizing the method
to achieve high speciﬁcity at a potential loss in sensitivity.
The predictive performance of the NetCTLpan method is validated on
large and MHC diverse data sets derived from the SYFPEITHI [80] and Los
Alamos HIV databases (http://www.hiv.lanl.gov/), and its performance has
been compared to other state-of-the-art CTL epitope prediction methods.
It has been suggested that supertype-speciﬁc diﬀerences exist in how
dependent MHC class I presentation of peptides is on transport via TAP
molecules [9, 5, 34, 102] and proteasomal cleavage [126]. Likewise, it has
been suggested that the rescaling procedure commonly used to correct for
possible discrepancies between the allelic predictors [108, 53, 52] could mask
genuine biological diﬀerence between MHC molecules and potentially lower
the epitope predictive performance [60]. In the context of the NetCTLpan
method, we investigate to what extend such diﬀerences are observed in large
data sets that are diverse with regard to both MHC restriction and CTL
epitopes.
2.3 Materials
SYF data set
The SYFPEITHI database [80] was used as the source of MHC class I lig-
ands. MHC class I binding peptides classiﬁed as ligands were downloaded
in August 2009. Altogether, the database contained 2,966 HLA class I lig-
and pairs. Considering only ligands with length of 8 to 11 amino acids (the
lengths for which the MHC class I binding predictor NetMHCpan can per-
form predictions), the data set consists of 2,752 unique HLA class I ligand
pairs. Data used for training the individual MHC class I pathway predic-
tors—MHC binding [68, 35], proteasomal cleavage [69], and TAP transport
eﬃciency [78]—was removed from the data set, downsizing it to 2,309 unique
HLA class I ligand pairs.
Peptides in the data set with only serotypic HLA assignment were as-
signed to the most common HLA allele in the European population for
this serotype (e.g., the serotype HLA-A*01 was assigned to the speciﬁc
allele HLA-A*0101). The HLA allele frequencies were obtained from the
dbMHC database (http://www.ncbi.nlm.nih.gv/mhc/). Subsequently, for
every peptide, the source protein was found in the UniProtKB/Swiss-Prot
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database [13]. If more than one matching protein was a possible source
for a peptide, the protein was selected with preference for human and
long protein sequences. Peptides without corresponding source protein in
UniProtKB/Swiss-Prot were searched against NCBI NR protein database
(http://www.ncbi.nlm.nih.gov). These steps consequently resulted in the
SYF data set consisting of 2,267 HLA class I ligand pairs with correspond-
ing source proteins, where 226 ligands are 8-mers, 1,443 are 9-mers, 430 are
10-mers, and 168 ligands belong to the group of 11-mers. Note, that HLA-C
ligands are included in these numbers. In the evaluation, HLA-C ligands are
merged to a separate test set.
HIV data set
The same HIV data set has been used as for the paper describing the orig-
inal NetCTL method [52]. For comparison reasons, the data set has not
been updated. The data set is derived from the Los Alamos HIV database
(http://www.hiv.lanl.gov/). It consists of 216 HLA class I ligand pairs with
corresponding source proteins covering the 12 supertypes [57].
Training and test sets
Each of the HLA alleles in the SYF data set was assigned a supertype as-
sociation using the distance measure described by Nielsen et al. [68]. In
short, an HLA allele was associated to the most similar supertype deﬁned in
terms of the correlation coeﬃcient between NetMHCpan prediction scores for
1,000,000 random natural 9-mer peptides for the HLA allele in question and
any of the 12 supertype representatives [53]. In a few cases (less than ten),
the supertype association was ambiguous. In these cases, the association was
assigned by applying the classiﬁcation from the work by [98]. The associated
supertypes for each HLA class I allele are shown in Supplementary Table S1.
Some supertypes in the 9-mer SYF data set contain more HLA class I ligand
pairs than others. Only four out of the 12 supertypes had more than 100
HLA class I ligand pairs assigned. In order to minimize bias toward only
a few supertypes, a training data set with maximum 50 randomly selected
ligands per supertype was generated. For seven supertypes, it was possible to
select 50 ligands for the training set, while the selection for the ﬁve remaining
supertypes consisted of between 19 and 47 ligands. This results in a training
set of 504 HLA class I ligand pairs. Remaining HLA-A and HLA-B ligands
not included in the training data were assigned to a separate set used for
evaluation. This evaluation set covers seven supertypes and consists of 889
9-mers. All HLA-A and HLA-B 8-, 10-, and 11-mer ligands were merged into
another evaluation set, resulting in a total of 806 ligands. The HIV data set
was used as a third independent evaluation set. The numbers of ligands per
supertypes for the training and test sets are listed in Table 2.1. Finally, a set
of 65 HLA-C ligands from the SYFPEITHI database of length 8–11 amino
acids was used as a fourth evaluation set.
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Table 2.1. Numbers of ligands per supertype in the training and test set.
Supertype Train Test 9-mer Test 8/9/10/11-mer HIV
A1 36 0 29 5
A2 50 208 94 82
A3 50 49 75 41
A24 19 0 5 9
A26 50 43 74 2
B7 50 8 57 32
B8 28 0 19 5
B62 47 0 27 10
B27 50 224 141 3
B39 50 21 36 1
B44 50 336 227 16
B58 24 0 22 10
Total 504 889 806 216
2.4 Methods
MHC class I aﬃnity prediction
The current version of the pan-speciﬁc MHC class I binding prediction
method, NetMHCpan-2.2 [35], is an updated version of the original NetMHC-
pan method [68]. It has been evaluated as the best pan-speciﬁc method in
large benchmark study [132] and is now including the extension to perform
predictions for 8-, 10-, and 11-mer peptides [59]. NetMHCpan-2.2 was trained
on a data set of 102,146 quantitative peptide–MHC aﬃnity data points cover-
ing more than 100 distinct MHC molecules. The prediction server is available
at http://www.cbs.dtu.dk/services/NetMHCpan-2.2/.
TAP transport eﬃciency prediction
The prediction of TAP transport eﬃciency is based on the matrix method
described in Peters et al. [78]. The method predicts TAP transport eﬃciency
of peptides by a scoring method using only the C terminus and the tree N-
terminal residues of a peptide. The contribution to the prediction score of the
N-terminal residues is down-weighted by a factor of 0.2 in comparison with
the score of the C terminus. In the original publication, the TAP transport
eﬃciency score was computed as the average of the values for the 9-mer and
its 10-meric precursor. Here, we extend this approach and predict the TAP
transport eﬃciency score for peptides of length from 8 to 11 amino acids, as
the average of the values for the original peptide and its precursor extended
by one amino acid N-terminally. The matrix published in Peters et al. [78]
was modiﬁed as all values in the TAP scoring matrix were multiplied by
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a factor of −1, in order to have a high predicted value corresponding to
high transport eﬃciency. This way the interpretation is consistent with the
prediction of proteasomal cleavage and MHC class I binding aﬃnity.
Proteasomal cleavage prediction
NetChop C-term 3.0 [69] was used for predicting cleavage sites. As in the
original NetCTL publication, only the C-terminal cleavage score of a peptide
was included.
Combined class I pathway presentation
prediction—NetCTLpan
The NetCTLpan prediction value is deﬁned as a weighted sum of the three
individual prediction values for MHC class I aﬃnity, TAP transport eﬃ-
ciency, and C-terminal proteasomal cleavage. Optimal relative weights on
TAP transport eﬃciency and proteasomal cleavage were estimated using the
training data set and based on the average AUC value per HLA class I ligand
pair.
The AUC measure is a commonly used measure for quantitative tests and
model comparison. AUC is the area under the ROC curve, summarizing the
sensitivity as a function of 1—the speciﬁcity. The speciﬁcity is given as 1—the
false positive ratio deﬁned as the fraction of the number of correctly predicted
nonligands relative to the total number of nonligands in the dataset [58]. A
speciﬁcity of 100% is interpreted as all nonligands are actually classiﬁed as
nonligands. The sensitivity is the true positive rate (TPR) and is deﬁned
as the number of correctly predicted ligands relative to the total number of
ligands in the dataset. The higher the TPR, the more actual positives are
recognized. The AUC measure might not be optimal if a prediction method is
required to have very high speciﬁcity in order to lower the false positive rate
in subsequent experimental validations. In such situations, it is beneﬁcial to
use only the high speciﬁcity part of the ROC curve to calculate the predictive
performance. Therefore, a search optimizing the AUC value integrated for
speciﬁcities from 1 to x (AUCx), where x [0:1] was performed to optimize the
method to achieve high speciﬁcity. High values of x will focus the method
toward high speciﬁcity at a potential loss in sensitivity, whereas low values
of x will result in equal focus on sensitivity and speciﬁcity.
When calculating the AUC value, the source protein was divided into
overlapping peptides of the size of the given ligand. All peptides, except those
annotated as ligands in either the complete SYFPEITHI or Los Alamos HIV
databases, were taken as negative peptides (nonligands) and the given ligand
was taken as positive. A perfect AUC value of 1.0 corresponds to the ligand
having the highest combined score (NetCTLpan score) compared to all other
possible peptides originating from the source protein.
Another important issue to resolve is how to calculate AUC values. Should
it have been done per protein, where an AUC value is calculated for each lig-
and–HLA–protein triplet and the performance reported as the average AUC
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value over all triplets or should it have been made in a pooled way, where
all peptide data for the diﬀerent source proteins and HLA alleles are merged
together before calculating the AUC value? Here, we suggest using the per-
protein measure, since pooling data from diﬀerent proteins and HLA alleles
will place ligands in a nonbiological competition for presentation. The source
proteins in the SYF ligand data sets have a length distribution varying from
36 to more than 8,000 amino acids. Applying the NetCTLpan method to our
training set (most homogenous data set) shows a tendency for shorter pro-
teins having a lower AUC0.1 than longer proteins. Proteins from our training
set with length of 0–200 have a mean AUC0.1 of 0.817, whereas proteins
longer than 200 AA have a mean AUC0.1 of 0.876. The Spearman’s rank
correlation between the protein length and AUC0.1 values for the training
data set is 0.15. This value is signiﬁcantly diﬀerent from random (p￿<￿0.001,
exact permutation test). In a pooled evaluation, where source protein data
are merged, the predictive performance would predominantly reﬂect the per-
formance for the longer protein. Further, not all proteins are expressed in
equal amounts within the cell and the presentation of peptides in complex
with HLA molecules happens in competition with the four most diﬀerent
HLA-A and HLA-B molecules within a given host and not 46, as it would
be the case, when all the HLA alleles from the SYF training data set are
pooled. Finally, it is becoming apparent that not all MHC molecules present
peptides at the same binding threshold [81]. This observation would make
an evaluation, where data for diﬀerent HLA alleles is pooled, highly prob-
lematic, as illustrated in Fig. 2.1. Here, a ROC curve is shown for a pooled
set of 29 HLA-A*0101, 50 HLA-B*4402, and 31 HLA-B*5101 ligands using
the NetCTLpan method. In addition, the allele-speciﬁc sensitivity (fraction
of ligands identiﬁed) for each allele is shown as a function of the pooled
speciﬁcity. The ﬁgure clearly demonstrates that diﬀerent alleles dominate
the ROC curve in diﬀerent speciﬁcity ranges. At a speciﬁcity of 0.0025, for
instance, 60% (66) of the 110 ligands are identiﬁed. Of these are 25 (86% of
29) HLA-A*0101, 32 (62% of 50) are HLA-B*4401, and only nine (29% of
31) are HLA-B*5101 restricted. At very high speciﬁcities, the ROC curve is
thus predominantly shaped by the HLA-A*0101 data, at intermediate speci-
ﬁcities values the curve is shaped by the HLA-B*4402 data, and ﬁnally at
low speciﬁcity values, the HLA-B*5101 data deﬁnes the curve. This is clearly
not an optimal way of evaluating an overall predictive performance of a pre-
diction method that is aimed at achieving uniform prediction accuracy across
a broad range of HLA alleles. To conclude, we ﬁnd that the proposed triplet
evaluation per ligand–HLA–protein evaluation constitutes the least biased
approach to evaluate a prediction method with broad allelic coverage.
2.5 Results
The NetCTLpan method
The optimal weights on proteasomal cleavage and TAP transport eﬃciency
were calculated for AUC fractions (AUCx) varying x from 0.05 to 1, with a
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Figure 2.1. ROC curves for a pooled data set from the HLA-A*0101, HLA-
B*4402 and HLA-B*5101 alleles. The source proteins for all three alleles
were cut into overlapping peptides of the size of the given ligand and all pep-
tides except the given ligands were taken as negative. The data set contained
31 HLA-A*0101, 50 HLA-B*4402, and 29 HLA-B*5101 ligands and the pre-
dictions were made using the NetCTLpan method. The black curve shows
the ROC curve for the combined data set. The other three curves show the
allele-speciﬁc sensitivity (fraction of ligands identiﬁed) as a function of the
overall speciﬁcity for each of the three alleles. The insert shows the curves
for the full range of speciﬁcities.
step size of 0.05. With x equal to 1, this corresponds to the conventional
AUC value calculation and the way of selecting optimal weights for the orig-
inal NetCTL method. The result of this analysis is shown in Fig. 2.2. For
an AUC fraction of 1, the optimal weights were zero on both proteasomal
cleavage and TAP transport. This implies that NetMHCpan 2.2, the method
used for predicting MHC class I binding aﬃnity, has a very high performance
and that adding predictions for proteasomal cleavage or TAP transport de-
creased the overall performance. Figure 2.2 illustrates that the more the
method is focused on high speciﬁcity (low values of x), the higher the weights
and thus importance of proteasomal cleavage and TAP transport predictions
become. This is, however, achieved at a loss in sensitivity at low speciﬁcity
values. Based on this observation, the best performing weights on proteaso-
mal cleavage and TAP transport were selected using an AUC fraction of 0.1
as benchmark measure and were found to be 0.225 for cleavage and 0.025
for TAP. This selection of weights deﬁnes the NetCTLpan method. When
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Figure 2.2. Weights on proteasomal cleavage and TAP transport eﬃciency
related to AUCx fraction. The smaller the included fraction, the higher the
contribution of proteasomal cleavage and TAP transport eﬃciency to a high
performance. Optimal weights on proteasomal cleavage and TAP were found
by optimizing the average AUCx value on the SYF training data set. The
dotted line indicates the AUC0.1 fraction.
interpreting the weights for cleavage and TAP, keep in mind that the con-
tribution of the diﬀerent prediction methods is not directly reﬂecting their
relative biological contribution in the pathway.
A comparison of the ROC curves for NetMHCpan and our described
method NetCTLpan is shown in Fig. 2.2. The overall AUC value for the
NetMHCpan method is 0.980 and the corresponding AUC0.1 value is 0.852.
For the NetCTLpan method, the overall AUC value is 0.976 and the corre-
sponding AUC0.1 value is 0.869. These numbers and the graphs in Fig. 2.2
illustrate the improved speciﬁcity of the NetCTLpan method compared to
NetMHCpan. Up to a speciﬁcity of 0.85, the ROC curve for NetCTLpan has
a higher sensitivity than NetMHCpan, indicating that this method will iden-
tify more true ligands at a given speciﬁcity threshold. On the other hand,
below a speciﬁcity of 0.85, the two ROC curves cross and the NetMHCpan
method achieves the highest sensitivity. This crossover, however, happens
at a very low speciﬁcity corresponding to a false positive rate of 0.15 (15%
of the negative peptides are falsely classiﬁed as positive) and is of limited
use when doing actual epitope discovery work, underlining the importance of
optimizing the methods on high speciﬁcity.
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Figure 2.3. Performance comparison in terms of ROC curves for NetCTL-
pan and NetMHCpan. The true positive rate is shown as a function of the
false positive rate. The ﬁgure is based on the SYF training set. The shaded
area shows the area under the curve used to calculate the AUC0.1. The insert
shows the complete curves.
Table 2.2 displays the comparison between NetCTLpan and NetMHCpan
for the diﬀerent data sets using both the overall AUC and AUC0.1 bench-
mark measures. Using the AUC0.1 measure, the NetCTLpan method has a
signiﬁcantly higher performance compared to NetMHCpan for all data sets.
On the other hand, when comparing the overall AUC value, the two methods
show comparable performance. Here, for the SYF data set, the NetMHC-
pan method has the highest performance, while for the HIV data set and the
HLA-C test set, NetCTLpan performs best. So, if high sensitivity is essential
(even at a cost in speciﬁcity), the NetMHCpan method should be preferred.
In more common situations, where speciﬁcity is the more important issue,
NetCTLpan should be the choice.
Results displayed in Table 2.2 are mean AUC and AUC0.1 values over all
ligand–HLA–protein triplets in each data set. Paired tests were used for com-
paring performance between diﬀerent prediction methods. In Supplementary
Table S2 are given the AUC and AUC0.1 values for each ligand–HLA–protein
triple in the SYFPEITHI data sets. From this table, it is clear that the pre-
dictive performance does not only vary between supertypes, but also within
supertypes. For the training data set, the diﬀerence between HLA-B*5101
and HLA-B*0702 (both B7 supertype alleles) for the NetCTLpan method is
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Table 2.2. AUC and fractional AUC value comparison between NetCTLpan
and NetMHCpan. The performance values are calculated as average per
protein AUC values over the corresponding data sets. P-values are calculated
by a paired t-test excluding ties. The best performing method is, for each
data set and performance measure, high-lighted in bold.
Data Measure NetCTLpan NetMHCpan P-value
Train (9) AUC 0.976 0.980 0.056
AUC0.1 0.869 0.852 0.002
Test (8/9/10/11) AUC 0.977 0.979 0.273
AUC0.1 0.863 0.855 0.002
Test (HIV) AUC 0.933 0.920 0.028
AUC0.1 0.612 0.593 0.106
Test (HLA-C) AUC 0.920 0.866 <0.001
AUC0.1 0.495 0.307 <0.001
Total 504 889 806 216
thus 0.374 in terms of the AUC0.1 measure. These performance variations
demonstrate the need for large-scale HLA diverse benchmark data set to
evaluate diﬀerences in performance between prediction methods, as the per-
formance diﬀerence between similar (supertype-wise) alleles often is as high
as the diﬀerence for individual alleles between two prediction methods within
a given data set.
Data redundancy
Several ligands appear in the SYFPEITHI ligand data sets as duplicates re-
stricted to multiple HLA class I alleles. One might be worried that the poten-
tial peptide similarity/redundancy could inﬂuence the performance estimates
of the NetCTLpan method. The training data set, for instance, consists of
504 HLA ligand pairs, but only 492 of these are unique peptides. The 9-mer
test set consists of 889 9mer HLA ligand pairs, of which 802 are unique pep-
tides. The training and 9-mer test sets share 42 identical ligands and three
ligands with one mismatch, all coupled to diﬀerent alleles. The training set
contains four ligands identical with one mismatch. To investigate the impact
on this data redundancy within the training data set and between the train-
ing and test data sets, we calculated the performance on redundancy-reduced
data sets. The performance on the training set was calculated by removing
duplicates and ligands with one mismatch and for the test set by excluding
duplicates and ligands with one mismatch to ligands in the training data.
Predictive performance was shown to be close to identical for both training
and test set, suggesting that peptide redundancy plays a negligible role in
our performance evaluation (see data in Supplementary Table S3).
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MHC aﬃnity rescaling
In contrast to the NetCTL method, the NetCTLpan method does not use
rescaling of predicted MHC class I aﬃnities. Previously, rescaling has been
used to make prediction values comparable between MHC class I molecules.
It has been suggested that such a rescaling might remove genuine biologi-
cal diﬀerences between MHC molecules and potentially lowers the epitopes
predictive performance [60]. To investigate, if the predictive performance
of the NetCTLpan method is inﬂuenced when including rescaling, we de-
ﬁned a rescaling factor for each MHC allele and used that factor to rescale
all MHC binding aﬃnity values before integrating with proteasomal cleav-
age and TAP scores. For each allele, the rescaling factor was determined
as the 1 percentile score of the NetMHCpan method for a set of 1,000,000
random natural 9-mer peptides. An overall performance gain using rescaling
as compared to not applying rescaling was observed if focusing on the over-
all AUC value (no rescaling AUC 0.976 versus rescaling AUC 0.978, p value
0.006, paired t test). For high speciﬁcity predictions (AUC0.1), however, the
method without rescaling performed similar (AUC0.1 0.869) to the method
using rescaling (AUC0.1 0.868) with a p value of 0.835. From these results,
and to maintain potential biological diﬀerences in speciﬁcity between MHC
molecules, we chose not to include rescaling in the NetCTLpan method. One
might argue that rescaling versus nonrescaling cannot inﬂuence the perfor-
mance of the NetCTLpan method, when the performance is calculated per
ligand–HLA allele, as it is the case in this study. When focusing on MHC
binding predictions alone, this is true and both methods give identical results.
However, when integrated with proteasomal cleavage and TAP transport eﬃ-
ciency, this situation changes. Rescaling places all MHC binding predictions
on a similar scale and hence also places the relative weights on TAP and
proteasomal cleavage on a similar scale across the set of MHC alleles. This
is no longer the case if rescaling is left out. Here, alleles with low (pre-
dicted) binding aﬃnity preference will have higher relative weights on TAP
and proteasomal cleavage as compared to alleles with high binding aﬃnity
preference.
Supertype-speciﬁc weights on proteasomal cleavage and
TAP scores
As mentioned earlier, previous work has suggested that diﬀerent MHC
molecules have diﬀerent dependencies on TAP transport eﬃciency and pro-
teasomal cleavage. Based on these observations, it seems natural to ﬁnd
allele-speciﬁc weights for TAP transport and proteasomal cleavage. Due to
the small size of the training data set, we limited ourselves to a search for
supertype-speciﬁc weights. For each supertype, we estimated the weights on
proteasomal cleavage and TAP transport that give optimal average AUC0.1
values. Optimal weights per supertype and performance values for the diﬀer-
ent data sets can be seen in Table 2.3. It shows that relative large diﬀerences
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exist between the optimal weights across the diﬀerent supertypes. Naturally,
the average AUC0.1 for the training set is higher with supertype-speciﬁc
weights as compared to the ﬁxed weights (estimate for the complete train-
ing data set). Applying these weights resulted in an inconsistent pattern in
performance gain across the diﬀerent supertypes for the diﬀerent test sets
when compared to ﬁxed weights. Only three supertypes (A24, B8, and B58)
showed a consistent performance gain for the SYFPHITHI and HIV test sets
using supertype-speciﬁc weights. This result strongly indicates that optimal
weights per supertype are not reﬂecting biological diﬀerences but occur most
likely due to overﬁtting. Note that we are not stating that proteasomal cleav-
age and TAP transport dependency could not vary between MHC molecules;
we only state that based on our data, we cannot consistently reproduce such
a diﬀerentiated dependency.
Comparison to NetCTL
The comparison of the performance between NetCTLpan and NetCTL is
based on the 9-mer data sets, since NetCTL is only capable of predicting
9-meric epitopes. Table 2.4 shows the performance for NetCTLpan and
NetCTL on the diﬀerent data sets. For both SYF data sets, the NetCTL-
pan method signiﬁcantly outperforms NetCTL. The HIV test set does not
show NetCTLpan being signiﬁcantly better than NetCTL. The HIV test set
is supertype based, and the HLA restriction for each HIV epitope is assigned
to the corresponding HLA supertype. This is in contrast to the SYF ligand
data sets, where full typing HLA restriction is available for most ligands.
One hundred nineteen out of 216 HIV peptide supertype pairs are, how-
ever, annotated in the Los Alamos HIV database with full typing for the
HLA restriction. Using this additional information about the HLA restric-
tion improves the mean AUC0.1 from 0.612 to 0.745 and the overall AUC
from 0.933 to 0.959. Both measurements thus testify NetCTLpan as having
a signiﬁcantly better performance (both p values <0.001, paired t test) com-
pared to NetCTL. These results clearly conﬁrm earlier ﬁndings [77, 35] of the
importance of going beyond HLA supertypes and the use of full-type HLA
restriction information when identifying MHC class I epitopes.
To determine the source of the strong gain in predictive performance be-
tween the NetCTL and NetCTLpan methods, we compared the predictive
performance of the NetCTLpan method to that of NetCTL using the su-
pertype representative for each HLA allele also for the NetCTLpan method.
This analysis clearly shows (see Table 2.5) that the shift from supertype to
allele-speciﬁc predictions is the main driving force behind the gain in pre-
dictive performance between NetCTL and NetCTLpan. In all benchmarks
has the NetCTLpan_ST (supertype-speciﬁc NetCTLpan method) a similar
predictive performance to that of NetCTL.
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Table 2.4. Benchmark comparison of the NetCTLpan and the NetCTL
methods. Average AUC and AUC0.1 values for the NetCTLpan and NetCTL
methods calculated for the SYF train set and the SYF and HIV test sets.
For each data set and performance measure, the best performing method is
shown in bold. P-values are calculated by a paired t-test excluding ties.
Data Measure NetCTLpan NetCTL P-value
Train (9) AUC 0.976 0.971 0.018
AUC0.1 0.869 0.816 <0.001
Test (9) AUC 0.982 0.975 <0.001
AUC0.1 0.877 0.802 <0.001
Test (HIV) AUC 0.933 0.936 (*) 0.366
AUC0.1 0.612 0.606 0.600
Table 2.5. Benchmark comparison of NetCTL, NetCTLpan and NetMHC-
pan_ST (supertype-speciﬁc version of NetCTLpan). The performance values
are calculated as average per protein AUC values for the training and test
data sets.
Data Measure NetCTL NetCTLpan NetCTLpan ST
Train (9) AUC 0.971 0.976 0.971
AUC0.1 0.816 0.869 0.830
Test (9) AUC 0.975 0.982 0.971
AUC0.1 0.802 0.877 0.805
Test (8/10/11) AUC NA 0.972 0.961
AUC0.1 NA 0.848 0.770
Comparison to state-of-the-art MHC class I pathway
prediction methods
Next, we compared the performance of the NetCTLpan method to the
MHC-pathway method [111]. This method has earlier been shown to be
a state-of-the-art MHC class I pathway predictor [53]. Like the NetCTL-
pan method, this method integrates predictions of MHC binding, C-terminal
proteasomal cleavage, and TAP transport into a combined pathway pre-
sentation score. Here, we use the method with default parameters via the
link http://tools.immuneepitope.org/analyze/html/mhc_processing.html. The
MHC-pathway method is not pan-speciﬁc and hence does not allow predic-
tions for all HLA class I alleles used in our benchmark data. Further, it does
not allow for predictions of 8- and 11-mer epitopes and only allows 10-mer
epitope predictions for a subset of the included alleles. To allow for a fair
comparison, we therefore only included ligands from the SYF data set re-
stricted to HLA alleles covered by the MHC-pathway method. The results
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of the benchmark calculation are shown in Table 2.6 and clearly show that
NetCTLpan outperforms the MHC-pathway method for all three data sets.
The improved performance is maintained for both the AUC and AUC0.1 mea-
sure. Further, the table shows that the MHC binding predictors for the two
methods have close to identical performance (NetMHCpan versus MHC).
The cleavage method employed by the NetCTLpan method is performing
consistently better than the immunoproteasome prediction method used by
MHC-pathway (NetChop versus Immu). The TAP prediction method is iden-
tical between the two methods. These results suggest that the integration
method employed by MHC-pathway is not optimal either due to the relative
low performance of the immunoproteasome predictor or as a consequence of
how the three prediction scores have been integrated in the MHC-pathway
method.
2.6 Discussion
Earlier work has demonstrated the beneﬁt of integrating proteasomal cleav-
age, TAP transport eﬃciency, and MHC binding predictions when using
reverse immunology to identify potential CTL epitopes. However, to the
best of our knowledge, none of the publicly available methods providing this
integration are pan-speciﬁc and hence do not allow for prediction of CTL
epitopes restricted to any MHC allele.
Here, we have developed a pan-speciﬁc MHC class I epitope predictor,
NetCTLpan. The method integrates prediction of proteasomal cleavage,
TAP transport eﬃciency, and MHC binding into a MHC class I pathway
presentation likelihood score. In large-scale benchmarks comprising more
than 1,000 MHC class I ligands and CTL epitopes restricted by close to 60
diﬀerent HLA alleles, the method was shown to outperform both the original
NetCTL method, as well as MHC-pathway, another state-of-the-art class I
presentation pathway prediction method.
NetCTLpan was optimized to achieve high speciﬁcity in order to meet
the need for a low false positive rate when using the method for large-scale
epitope discovery. If focusing on optimal sensitivity, it was shown that the
optimal prediction method should exclude both cleavage and TAP predictions
reducing the method to MHC binding prediction alone. This is in contrast to
earlier work, where proteasomal cleavage and TAP transport eﬃciency con-
sistently have been reported to improve the predictive performance. Whether
this observation reﬂects true biological aspects of the speciﬁcity overlap be-
tween the three pathway players (see for instance Nielsen et al. [69]) or it
simply occurs because the prediction of MHC class I aﬃnity has gained accu-
racy during the recent years, whereas predictors for TAP transport eﬃciency
and proteasomal cleavage have not changed or been updated, remains to be
seen.
Recent publications have suggested that some MHC molecules are, com-
pared to others, more or less dependent on TAP transport and proteasomal
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cleavage. Using the NetCTLpan method in large-scale benchmarks, we how-
ever ﬁnd no consistent signal of such an HLA allele diﬀerentiated dependency
of proteasomal cleavage and TAP transport eﬃciency. A performance gain
using supertype-speciﬁc weights could only be observed for the training set.
Applying these weights to the test sets resulted in an inconsistent pattern
in performance gain for the diﬀerent supertypes when compared to ﬁxed
weights, indicating that optimal weights per supertype are not reﬂecting bi-
ological diﬀerences but most likely are a result of overﬁtting.
NetCTL, the ancestor of NetCTLpan, uses a rescaling of MHC binding
aﬃnity values to make prediction values comparable between MHC class I
molecules. It has been suggested that such a rescaling might remove gen-
uine biological diﬀerences between MHC molecules and potentially lower the
method’s predictive performance. Here, we show that rescaling has no signiﬁ-
cant impact on the overall predictive performance of the NetCTLpan method.
Further, we observed a tendency of diﬀerent MHC molecules presenting lig-
ands at diﬀerent (predicted) binding thresholds. Based on these observations,
the NetCTLpan method is implemented without use of rescaling, thus main-
taining potential genuine biological diﬀerences between MHC molecules. To
allow comparison between presentation likelihood scores for diﬀerent MHC
molecules, we include a rank-score for each prediction. The rank-score is cal-
culated as the percent rank of a given NetCTLpan likelihood score to a set
of 200,000 random natural 9-mer peptides.
Our results on the HIV benchmark data set conﬁrm the importance of
going beyond HLA supertypes and use full-type HLA restriction information
when identifying MHC class I epitopes. In this benchmark, we found a signif-
icantly improved predictive performance, if full HLA restriction were used,
in comparison to the HLA supertype information proposed in the original
NetCTL publication.
In contrast to earlier published methods for MHC class I pathway predic-
tion, NetCTLpan allows for predictions of 8- to 11-mer CTL epitopes being
presented by any MHC class I molecule of known protein sequence.
NetCTLpan, the method described in this work, has shown to perform
best when focusing on high speciﬁcity predictions for CTL epitope identiﬁca-
tion. In order to easily grasp the predictive performance gain, we applied the
rank measure as deﬁned by Larsen et al. [53]. The rank measure reports the
average fraction of epitopes identiﬁed as a function of the percentage rank
(percentage of tested peptides) for a set of proteins. This measure indicates
how large a fraction of the peptides for a given protein needs to be tested
in order to identify the epitope with a given likelihood. To identify new epi-
topes with 90likelihood by use of NetCTLpan, the rank measure reports that
3.7peptides need to be experimentally veriﬁed. For a hypothetical protein of
300 peptides, this means that on average, 11 peptides need to be tested in or-
der to identify the epitope. The corresponding numbers for NetMHCpan and
NetCTL are 13 and 17 peptides. Hence, by applying the NetCTLpan method
instead of NetMHCpan, the experimental eﬀort can be reduced by 17approx-
imately 40that utilizing the NetCTLpan method can minimize experimental
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eﬀort needed to identify new CTL epitopes. We believe that this improved
performance, combined with the methods ability to provide predictions of po-
tential CTL epitopes of length from 8 to 11 amino acids to any MHC class I
molecules of known sequence, will be useful in both rational reverse immuno-
genetic epitope discovery and interpretation of observed immune responses
in HLA diverse patient cohorts. The NetCTLpan method and benchmark
data set are available at: http://www.cbs.dtu.dk/services/NetCTLpan.
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3.1 Abstract
Several studies have shown that cancers actively regulate alternative splic-
ing. Altered splicing mechanisms in cancer lead to cancer-speciﬁc transcripts
diﬀerent from the pool of transcripts occurring only in healthy tissue. At
the same time, altered presentation of HLA class I epitopes is frequently ob-
served in various types of carcinoma. Down-regulation of genes related to
HLA class I antigen processing has been observed in several cancer types,
leading to fewer HLA class I antigens on the cell surface. Here, we show
that peptides unique to cancer splice variants comprise signiﬁcantly fewer
predicted HLA class I epitopes compared to peptides unique to normal tran-
scripts. Peptides unique to carcinoma transcripts are in the case of the three
most common HLA class I supertype representatives consistently found to
contain fewer predicted epitopes compared to normal tissue. We observed
a signiﬁcant diﬀerence in amino acid composition between unique normal
and carcinoma protein sequence as transcripts uniquely found in carcinoma
are enriched with hydrophilic amino acids. This variation contributes to
the observed signiﬁcant lower likelihood of carcinoma-speciﬁc peptides to be
predicted epitopes compared to peptides found uniquely in normal tissue.
3.2 Introduction
Cancer-speciﬁc splice variants are of signiﬁcant interest as they may be in-
volved in pathogenesis and may further potentially be used as biomarkers and
generate novel targets for cancer therapy [112, 101]. The human immune sys-
tem is capable of responding to some of these cancer speciﬁc antigens, as ﬁrst
shown by a melanoma-speciﬁc antigen, MAGE-1, able to stimulate human
T cells [115, 26]. More generally, individuals with high or medium cytotoxic
activity are further associated with a signiﬁcantly lower risk of cancer, sug-
gesting a role for natural immunological host defense mechanisms in cancer
[37]. Alternative splicing can change the structure of mRNA by inclusion or
skipping of exons, and this may alter the function, stability or binding prop-
erties of encoded proteins and thereby contribute to human diseases, such
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as cancer [67]. In a study investigating alternative splicing events in ovar-
ian and breast tissues aﬀected by tumors it was found that about half of all
splicing events in these tissues are altered in tumors, many of them due to
exon skipping [117]. Similar trends have been seen in other types of cancers,
e.g. in colon cancer and testicular tumor [33, 27], as well as in gastric can-
cer, where genes showing diﬀerential expression between cancer cell lines and
corresponding normal tissues were found [72]. In addition to cancer being
involved in dysregulating pathways, thus contributing to changes in alter-
native splicing and gene expression controlled by these proteins [16], human
leukocyte antigen (HLA) class I antigen processing components and HLA ex-
pression have also been shown to be downregulated in connection with cancer
[97, 90]. A study investigating alterations of HLA class I expression in 12
ovarian cancer patients reported low levels of HLA class I antigens in tumor
cells from all patients. One patient-derived tumor cell line showed a complete
haplotype loss, including the HLA-A2 locus [71]. These observations are in-
terpreted as mechanisms adopted by tumors to escape immune surveillance
and to avoid tumor cell recognition and destruction [62, 24]. It has been sug-
gested that elimination of growing tumors by the immune system may lead
to selection of tumor variants that are eﬃcient in avoiding immune system
recognition [123]. There thus seems to be accumulative evidence for cancer
being coupled to alternative splicing as well as to an eﬃcacy in evasion from
the immune system by downregulation and altering HLA expression. Most
of the studies relating cancer-speciﬁc alternative splicing to altered immune
system surveillance are, however, of limited size and in most cases anecdotal.
Here, we wanted to investigate, in a large scale study, if the alternative cancer
exome already at the step of mRNA splicing would contain a bias compared
to normal transcripts in the set of possible HLA class I epitopes.
3.3 Materials and Methods
Data extraction from the ASTD database
The Alternative Splicing and Transcript Diversity database (ASTD) provides
access to a collection of alternative splice events and transcripts of genes from
human, mouse and rat [49]. The aim of the database is to analyze the mech-
anisms of alternative splicing on a genome-wide scale. It integrates a compu-
tational pipeline for detection and characterization of isoform splice patterns
as well as alternative introns and exons. Our study is based on ASTD ver-
sion v1.1 build 9. The database covers 14,194 human genes and lists 50,581
unique transcripts not covered by Ensembl genes. Based on related evidences
from cDNA libraries, many of these transcripts are tagged with pathology in-
formation. The pathology information is given as eVOC ontologies, which is
a controlled vocabulary for unifying gene expression data [43]. Two data sets
were generated based on annotated pathology information. All transcripts
tagged with the information of being expressed in normal tissue were assigned
to subset N. This subset consisted of 30,739 transcripts derived from 11,980
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Burkitt´s lymphoma Glioblastoma Myeloid leukemia
Ewing´s sarcoma Glioma Myeloma
T-cell leukemia Hypertrophic cardiomyopathy Neoplasia
Wilms tumor Insulinoma Neuroblastoma
Adenocarcinoma Leiomyosarcoma Oligodendroglioma
Adenoma Leukaemia Osteosarcoma
Astrocytoma Liposarcoma Papillary serous carcinoma
Carcinoid Lymphoblastic leukemia Phaeochromocytoma
Carcinoma Lymphocytic Polyp
Carcinoma in situ Lymphoma Retinoblastoma
Chondrosarcoma Aalignant tumour Rhabdomyosarcoma
Choriocarcinoma Medulloblastoma Sarcoma
Enchondroma Melanoma Seminoma
Fibrosarcoma Meningioma Teratocarcinoma
Fibrothecoma Monocytic leukemia Tumour
Table 3.1. eVOC terms used for carcinoma subset.
Normal Carcinoma
Number of transcripts 30,739 27,967
Number of genes 11,980 10,730
Number of uniquely associated transcripts 16,566 13,794
Number of uniquely associated genes 8,741 7,128
Average number of unique transcripts / gene 1.90 1.94
Table 3.2. Number of transcripts and genes per set. Transcripts were ex-
tracted from the ASTD database. Number of transcripts and genes associated
with normal and carcinoma pathology terms are given.
genes. A second subset, C, with transcripts related to carcinoma, consisted
of 27,967 transcripts derived from 10,730 genes. The carcinoma subset con-
sists of all transcripts tagged with eVOC terms related to carcinoma; that
is being a subgroup of tumor in the eVOC ontology hierarchy (Table 3.1).
Several eVOC terms can be associated to the same transcript. For our ana-
lysis, we were interested in transcripts uniquely associated to normal tissue
or to one or more of the carcinoma eVOC terms. Two new subsets consist-
ing of transcripts only associated to either normal or carcinoma eVOC terms
were created. Out of 30,739 transcripts associated to normal, 16,566 were
uniquely associated with normal tissue and not with carcinoma (unique N
set). The subset of transcripts uniquely associated with carcinoma (unique
C set) consists of 13,794 transcripts (see Table 3.2).
Translation to proteins
All transcripts assigned to either normal or carcinoma pathology were trans-
lated to their respective protein sequence using Virtual Ribosome [125]. The
longest ORF among all three reading frames was chosen as the translated
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Figure 3.1. Lengths of transcripts and their respective proteins for tran-
scripts assigned to normal and carcinoma groups.
protein sequence. The protein sequence and corresponding transcript were
discarded if no ORF was found or if the resulting protein sequence was shorter
than 9 amino acids. The threshold of 9 amino acids was chosen as we sub-
sequently apply the epitope prediction on 9-meric peptides, although we are
aware that proteins this small might not be functional. Applying this ﬁlter
resulted in a normal set of 16,490 transcripts and a carcinoma set of 13,721
transcripts. The distribution of transcript and protein length is shown in
Figure 3.1. The average length of transcripts from normal tissue is 1,004 nu-
cleotides; carcinoma transcripts have an average length of 1,078 nucleotides.
The average protein lengths are 185 and 212 amino acids, for normal and
carcinoma transcript, respectively.
Generation of unique 9-mers
All proteins assigned to either normal or carcinoma pathology states were
divided into overlapping 9-meric peptide sequences. Peptide sequences that
were found in both groups were removed, leading to the creation of two sets
of unique 9-mer peptides. There are 1,856,231 unique 9-mers in the normal
group (N-peptidome) and 1,684,028 unique 9-mers in the carcinoma group (C-
peptidome). Note that normal and carcinoma sets do not consist of complete
proteins; they only consist of unique 9-meric peptides not found in the other
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set. Permutated sets of both the unique N and unique C set were created.
For each set, one locally permutated and one globally permutated set of 9-
meric peptides was generated. The local permutated sets were constructed by
permuting each 9-mer, thus keeping the amino acid composition within each
9-mer ﬁxed. The global permutated sets were made by randomly constructing
new 9-mers out of all amino acids within each set. This preserves the overall
amino acid composition within the unique N and C sets, local properties
within each 9-mer are, however, destroyed.
Prediction of possible HLA class I epitopes
The prediction method NetMHCpan-2.4 [35, 68] was used for predicting po-
tential epitopes for the 12 HLA class I supertypes [57]. In practice, putative
epitopes for a given HLA class I supertype were identiﬁed by predicting which
peptides are presented by a speciﬁc HLA class I allele that represents the en-
tire supertype (for example, HLA-A*0201 represents the A2 supertype). The
NetMHCpan-2.4 method was trained on an experimentally validated data
set of more than 100,000 quantitative peptide – HLA class I interactions
covering more than 100 HLA molecules and has been evaluated as the best
pan-speciﬁc method for HLA peptide binding in a large benchmark study
[132]. A general accepted threshold for binding is a rank score of 1% [22, 81]
(binding strength falling within the top 1% compared to a large set of random
natural peptides), which is also the threshold, used throughout this study.
The percentages of potential epitopes per 9-mer for all 6 sets (normal
9-mers, normal globally permutated 9-mers, normal locally permutated 9-
mers, carcinoma 9-mers, carcinoma globally permutated 9-mers and carci-
noma locally permutated 9-mers) were calculated. P-values for diﬀerence
in percentage of predicted epitopes between normal and carcinoma 9-mers
for non-permutated and permutated subsets were calculated by a 2-sample
test for equality of proportions and adjusted for multiple testing (Bonferroni
correction).
Amino acid scales
The amino acid abundance for normal tissue compared to carcinoma tissue
was determined based on all unique 9-mers in the two data sets. The relative
frequencies for all amino acids in both the normal and carcinoma sets were
calculated. Observed ratio of frequencies (N/C) of amino acids among normal
and carcinoma tissues was correlated with Hopp-Woods hydrophilicity [36]
and Wimley-White hydrophobicity scale [128] values. The ratio was further
correlated with a mean ranking scale per amino acid as published by Simpson
[100]. According to Simpson, the scale is based on the mean ranking of amino
acids according to the frequency of their occurrence at each sequence rank
for 38 published hydrophobicity scales [113]. Other investigated scales are
average volume of buried residues [84, 6], van der Waals volume [66] and
total accessible surface area [61].
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Allele Frequency
HLA-A*02:01 0.47
HLA-A*01:01 0.30
HLA-A*03:01 0.26
HLA-B*07:02 0.24
HLA-B*08:01 0.22
HLA-A*24:02 0.13
HLA-B*40:01 0.10
HLA-B*15:01 0.07
HLA-B*27:05 0.06
HLA-A*26:01 0.05
HLA-B*39:01 0.02
HLA-B*58:01 0.02
Table 3.3. Phenotype frequencies. HLA frequencies in the European popu-
lation. Data obtained from the dbMHC database [93].
Bootstrapping was applied to test if an amino acid property scale is cor-
related with enriched expression of residues in either unique normal or carci-
noma 9-mers. For each scale, the Spearman rank correlation coeﬃcient was
calculated and the signiﬁcance of the correlation was estimated using exact
permutation test.
HLA motif bias
HLA binding motifs were generated from NetMHCpan-2.4 training data. Po-
sition speciﬁc weight-matrices were calculated using sequence weighting and
correction for low counts [70]. Sequence logos were visualized as described by
Schneider and Stephens [95], where each letter represents its proportional fre-
quency of the corresponding amino acid at that position. Based on amino acid
frequencies and observed ratio of frequencies (N/C) of amino acids among
normal and carcinoma tissues, we calculated for the HLA-A*A02:01, HLA-
A*A01:01 and HLA-A*A03:01 motifs their respective overall bias towards
either our unique normal or carcinoma peptide set. This was done for all 20
amino acids and for the 5 most frequent amino acid occurrences per motif.
Per position, the tendency to ﬁt preferably to either the normal or the carci-
noma peptidome was calculated by summation of the respective amino acid
frequencies multiplied with the related N/C values for all 20 amino acids.
Likewise the calculation for the 5 most frequent amino acid occurrences per
motif, where only the subset of the motif´s 5 most frequent amino acid occur-
rences at this position is considered. Similar to the N/C ratio, a motif´s bias
to preferably ﬁt to our normal set is given, if the average over all position for
a motif is larger than 1.
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3.4 Results
For the three most common HLA class I supertypes,
carcinoma transcripts contain fewer predicted epitopes
The aim of this study was to investigate, using a large-scale data set, if
peptidomes speciﬁc for cancer and normal tissue have diﬀerential proper-
ties related to altered degree of immune system surveilance. To do this, we
constructed two sets of peptides, one speciﬁc to carcinoma tissue and one
uniquely expressed in normal tissue. Globally permutated versions of these
sets were produced as described in Material and Methods. The global per-
mutation destroys structural characteristics within the MHC binding 9-mers,
only maintaining global compositional properties. For comparison, we con-
structed locally permutated normal and carcinoma sets by permutating each
peptide separately thus preserving the local amino acid composition of each
peptide. To investigate immune-related properties, potential epitopes cov-
ering all 12 HLA class I supertypes were predicted using NetMHCpan. For
each supertype, we calculated the percentages of predicted epitopes for the
six peptide data sets: normal, normal globally and normal locally permu-
tated, carcinoma and carcinoma globally and carcinoma locally permutated.
It is well known that some HLA class I supertype representatives are more
common than others. It is therefore expected that for the less frequent HLA
alleles the results are more likely to be more noisy. The source of our data
set, the ASTD database, is to a large extent originating from EST data
without HLA speciﬁc information. EST data is mostly based on Caucasian
Europeans [28]; therefore we can safely assume that the more common HLA
types in the European population are also more common in our dataset. The
HLA allele frequencies were obtained from the dbMHC database [93]. Ap-
proximate numbers of expected phenotype per supertype in the European
population are given in Table 3.3. The three most common supertype repre-
sentatives in the European population are HLA-A*02:01, HLA-A*01:01 and
HLA-A*03:01. For these three supertype representatives, the transcripts as-
sociated with normal tissue have a signiﬁcantly higher percentage of predicted
epitopes than transcripts uniquely found in carcinoma. Figure 3.2 shows the
observed numbers, in percentages of predicted epitopes per 9-mers, for the
diﬀerent data sets for these three most common supertype representatives.
All observed diﬀerences between normal and carcinoma tissues shown in Fig-
ure 3.2 are signiﬁcant (p < 0.006, 2-sample test for equality of proportions).
For most HLA class I supertypes, carcinoma transcripts
contain fewer predicted epitopes
Further, the percentage of predicted epitopes for permutated and not-
permutated sequences for all 12 supertype representatives is shown in Table
3.4. Here, we observed a similar tendency as compared to our observation
for the three most common supertypes in the European population. For
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Figure 3.2. Percentage of epitopes per 9-mer comparison. Data is shown for
the three most common HLA-I alleles in the European population. Each bar
shows the percentage of predicted epitopes per 9-mer in the respective set.
Each set consists of peptides that are either unique for normal or carcinoma
tissue. Globally permutated or locally permutated version of the peptide
sets were constructed as described in materials and methods. Based on each
respective scale, more hydrophobic amino acids are colored green and more
hydrophilic amino acids are colored red.
non-permutated sequences, seven out of the twelve supertype representatives
(HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*24:02, HLA-A*26:01,
HLA-B*15:01 and HLA-B*58:01) had a signiﬁcant lower fraction of predicted
epitopes in sequences assigned to carcinoma pathology. A statistical signiﬁ-
cant diﬀerence, where unique carcinoma peptides contained more predicted
epitopes was, on the other hand, only observed for one supertype representa-
tive, namely HLA-B*27:05. When analyzing permutated sequences, similar
results were observed. Only one supertype representative (HLA-B*40:01,
locally permutated) had signiﬁcantly more predicted epitopes in the permu-
tated carcinoma sequences than in the permutated normal sequences. On
the other hand, permutated, normal sequences had consistently for both the
local and global permutated sets more predicted epitopes for seven supertype
representatives (HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*24:02,
HLA-A*26:01, HLA-B*15:01, HLA-B*58:01). For these seven supertype rep-
resentatives, the diﬀerence between normal and carcinoma data sets is sig-
niﬁcant in the permutated as well the non-permutated data sets. The obser-
vation that carcinoma transcripts contain fewer predicted epitopes for most
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HLA class I supertype representatives, is stable, when diﬀerent thresholds
for the prediction of potential epitopes are applied (data not shown).
HLA motif and amino acid composition biases in carcinoma
sequence
The relative diﬀerence in predicted epitope density between normal and car-
cinoma is, for our previously deﬁned most common HLA molecules, relatively
stable. Also, the diﬀerence in epitope density is largest when comparing non-
permutated to globally permutated peptide sets. For HLA-A*02:01, a notice-
able decrease of predicted epitopes is observed when comparing normal and
carcinoma non-permutated peptides to normal and carcinoma permutated
peptides. As seen from Table 3.4 and Figure 3.2, the diﬀerence in percentage
of epitopes is the largest when comparing the non-permutated sequences to
the globally permutated sequences (normal: 0.83 vs 0.73, carcinoma: 0.77 vs
0.69). For HLA-A*01:01, the percentage of epitopes in non-permutated ver-
sus permutated sequences appears to be relative stable (normal: 0.82 vs 0.80,
carcinoma: 0.77 vs 0.76), whereas permutated HLA-A*03:01 sequences have
more predicted epitopes than the corresponding non-permutated sequences
(normal: 0.94 vs 1.01, carcinoma: 0.91 vs 0.96). For these three supertype
representatives, the percentage of predicted epitopes in locally permutated
peptides always falls between the respective percentages for non-permutated
and globally permutated sequences. Locally permutated peptides preserve
only local amino acid composition, and globally permutated peptides have
their local structural properties destroyed and preserve only global amino acid
composition. These observations indicate that both global and local struc-
tural amino acid properties are factors that deﬁne the observed diﬀerences
in the epitope densities between the normal and carcinoma peptidome. An
analysis of relative amino acid composition was done for all unique normal
and carcinoma 9-mers. We found that hydrophilic residues are more common
in unique carcinomic sequences as compared to normal sequences. The rela-
tions of N/C ratios compared to the hydrophilicity scale of amino acids by
Hopp-Woods, the hydrophobicity scale by Wimley-White as well as the mean
ranking of amino acids according to the frequency of their occurrence for 38
published hydrophobicity scales are shown in Figure 3.3. The Hopp-Woods
andWimley-White scales correlate strongly with the N/C ratios with a Spear-
man rank correlation coeﬃcient of -0.72 and 0.78, respectively. The mean
ranking amino acid scale is correlated with a correlation coeﬃcient of -0.65.
All three correlation coeﬃcients are signiﬁcant (p-value < 0.003, exact per-
mutation test). No correlation was found for other amino acid properties like
mass, surface area or volume (data not shown). It is striking to observe that
all strong hydrophilic amino acids (KPRQ, Hopp-Woods scale) are enriched
in sequences unique to carcinoma. A similar observation is made for Wimley-
White scale: We identiﬁed seven amino acids signiﬁcantly more common in
carcinoma (APERKDQ). Six out of these (all except A) are within the seven
most hydrophilic amino acids based on the Wimley-White scale. A reversed
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trend is found for hydrophobic amino acids. The top signiﬁcant amino acids
classiﬁed by both Hopp-Woods and Wimley-Scott as hydrophobic (WFICM)
are all more common in sequences uniquely assigned to transcripts from nor-
mal tissue. Based on these ﬁndings, one could suggest an explanation for the
diﬀerence in epitope density between the normal and carcinoma peptidome.
The binding motifs for the 3 most frequent supertype representatives are
shown in Figure 3.4. Four amino acids (VMIA), which are preferred at the
HLA-A*02:01 anchor positions are enriched in normal transcripts, whereas
only one (L) is as common in normal as in carcinoma. This leads to the obvi-
ous conclusion that at least part of the observed diﬀerences in percentage of
predicted epitopes in normal versus carcinoma transcripts are due to amino
acid composition. The same tendency is found for HLA-A*01:01. The two
most frequent amino acids in the motif (YT) are also more often found in nor-
mal tissue, whereas S is neutral and the next common amino acid, D, is more
common in carcinoma. The most frequent amino acid for HLA-A*03:01(K)
is slightly more common in carcinoma, whereas the second-next frequent (Y)
is, due to a stronger preference to ﬁt peptides from normal tissues, shifting
the bias towards amino acids more common in unique normal splice variants.
For all three motifs, we further calculated average weighted biases, based on
N/C ratios and amino acid frequencies (see materials and methods). Cov-
ering the respective 5 most frequent amino acids per motif as well as all 20
amino acids, we observed for all three motifs an overall preference for amino
acids found in our normal tissue set.
3.5 Discussion
Alternative splicing of mRNA transcripts is an important mechanism for
generating genomic complexity and has been shown to diﬀer between car-
cinoma and the corresponding normal tissues [112, 33, 27]. In addition,
cancers in some cases downregulate HLA class I antigen-processing compo-
nents and HLA class I expression to avoid detection by the immune system.
These observations led us to investigate whether transcripts found in cancer
tissue share characteristics that would reduce immune system recognition.
Here, we have carried out a large-scale analysis aiming at identifying im-
mune system related imprints that can diﬀerentiate carcinoma from normal
transcripts. We identiﬁed two peptide data sets, one uniquely associated with
carcinoma transcripts and one uniquely associated with normal transcripts.
Using state-of-the-art immunoinformatics predictions tools, we next analyzed
the two data sets for diﬀerences in terms of likelihood of being presented on
prevalent HLA class I molecules, and hence potential for activating the im-
mune system. We found that peptides, which due to alternative splicing
are uniquely expressed in carcinoma tissue, contain fewer predicted epitopes
restricted by the three most common HLA class I alleles than peptides ex-
pressed uniquely in normal tissue. Using globally permuted data sets we
consistently, for the three most common HLA class I alleles, found that the
observed loss in epitope density in the carcinoma peptidome is maintained
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Figure 3.3. Hydrophilic amino acids are enriched in carcinoma. N/C ra-
tios in relation to Hopp-Woods hydrophilicity scale (A), Wimley-White hy-
drophobicity scale (B) and to the mean ranking of amino acids based on 38
hydrophobicity scales (C). N/C ratio is the ratio of observed frequencies of
the respective amino acids among normal and carcinoma tissues. Residues
where N/C > 1 are more common in normal tissue; residues where N/C <
1 are more common in sequence assigned to carcinoma. Green bars refer to
more hydrophilic amino acids whereas black bars refer to more hydrophobic
amino acids. All N/C ratios larger or smaller one are signiﬁcant (p < 0.001,
calculated using the Wilson score [127] and Bonferroni corrected).
3.5. DISCUSSION 45
A
lle
le
%
ep
ito
pe
s
%
ep
ito
pe
s
gl
ob
al
ly
pe
rm
ut
at
ed
%
ep
ito
pe
s
lo
ca
lly
pe
rm
ut
at
ed
N
C
N
/C
P-
va
l
N
C
N
/C
P-
va
l
N
C
N
/C
P-
va
l
HL
A-
A*
01
:01
0.8
2
0.7
7
1.0
6
0.0
00
0.8
0
0.7
6
1.0
6
0.0
00
0.8
1
0.7
6
1.0
7
0.0
00
HL
A-
A*
02
:01
0.8
3
0.7
7
1.0
8
0.0
00
0.7
3
0.6
9
1.0
5
0.0
00
0.7
9
0.7
1
1.1
0
0.0
00
HL
A-
A*
03
:01
0.9
4
0.9
1
1.0
4
0.0
02
1.0
1
0.9
6
1.0
5
0.0
00
0.9
6
0.9
2
1.0
4
0.0
05
HL
A-
A*
24
:02
0.8
9
0.7
9
1.1
3
0.0
00
0.7
7
0.7
0
1.1
1
0.0
00
0.8
9
0.7
7
1.1
5
0.0
00
HL
A-
A*
26
:01
0.7
6
0.7
1
1.0
7
0.0
00
0.7
0
0.6
6
1.0
6
0.0
00
0.7
1
0.6
8
1.0
5
0.0
01
HL
A-
B*
07
:02
1.2
9
1.3
0
1.0
0
1.0
00
1.2
7
1.2
9
0.9
9
1.0
00
1.2
5
1.2
8
0.9
7
0.0
54
HL
A-
B*
08
:01
1.0
2
1.0
3
0.9
9
1.0
00
1.0
0
0.9
9
1.0
1
1.0
00
0.9
7
0.9
7
1.0
0
1.0
00
HL
A-
B*
15
:01
0.8
6
0.7
9
1.0
9
0.0
00
0.8
3
0.7
7
1.0
8
0.0
00
0.8
5
0.7
9
1.0
7
0.0
00
HL
A-
B*
27
:05
0.9
9
1.0
2
0.9
7
0.0
21
0.9
9
1.0
0
0.9
8
1.0
00
1.0
4
1.0
4
0.9
9
1.0
00
HL
A-
B*
39
:01
0.9
7
0.9
6
1.0
2
0.9
85
1.0
5
1.0
2
1.0
2
0.2
21
1.0
1
1.0
0
1.0
1
1.0
00
HL
A-
B*
40
:01
0.8
7
0.8
9
0.9
8
1.0
00
1.0
3
1.0
6
0.9
8
0.3
25
0.9
5
0.9
9
0.9
6
0.0
02
HL
A-
B*
58
:01
1.0
1
0.9
1
1.1
1
0.0
00
0.9
9
0.8
9
1.1
0
0.0
00
0.9
8
0.9
1
1.0
8
0.0
00
Ta
bl
e
3.
4.
Ep
ito
pe
sp
er
se
tf
or
all
su
pe
rty
pe
re
pr
es
en
ta
tiv
es
.P
er
ce
nt
ag
eo
fp
re
di
ct
ed
ep
ito
pe
si
sg
ive
n
fo
rd
at
a
ex
tra
ct
ed
fro
m
AS
TD
da
ta
ba
se
as
we
ll
as
for
pe
rm
ut
at
ed
se
qu
en
ce
s.
N/
C
is
th
er
at
io
be
tw
ee
n
th
en
or
m
al
an
d
ca
rc
in
om
ap
er
ce
nt
ag
es
.P
-va
lu
es
ar
ec
alc
ul
at
ed
by
tw
o-
ta
ile
d
tt
es
ta
nd
ad
ju
ste
d
for
mu
lti
pl
et
es
tin
g
by
Bo
nf
er
ro
ni
co
rre
ct
ion
.
46
CHAPTER 3. THE EPITOPE DENSITY IN THE ALTERNATIVE
CANCER EXOME
0
1
2
|
1
PDCE
H
Q
W
N
T
M
R
V
G
I
S
K
A
Y
L
F
2
HWERDY
N
P
K
C
G
F
S
A
Q
T
V
I
M
L
3
CRE
K
H
P
Q
W
T
N
G
V
M
S
D
Y
A
F
I
L
4
MHWC
Y
V
Q
R
F
K
N
I
T
P
L
S
A
G
E
D
5
MCHQP
W
K
R
N
E
D
T
S
A
F
Y
G
I
V
L
6
WH
K
R
E
C
Y
D
Q
M
P
G
A
N
F
S
T
V
I
L
7
RC
K
M
G
Q
W
N
E
D
H
S
T
Y
P
V
I
A
F
L
8
CWMHD
Q
N
K
R
I
V
Y
P
T
E
A
G
F
S
L
9
HWPDNK
E
Q
Y
C
R
G
F
S
M
T
A
I
L
V|
0
1
2
|
1
QPWDH
R
K
E
N
M
T
C
S
G
A
I
V
Y
F
L
2
WH
Y
P
F
N
D
K
E
R
C
Q
G
M
I
A
L
V
S
T
3
W
C
H
R
M
Y
V
K
Q
P
F
I
L
T
G
N
A
S
E
D
4
WCHM
Y
Q
R
P
F
K
I
S
N
V
T
A
E
G
D
L
5
HCWMPD
Q
K
R
E
A
I
N
T
Y
F
G
S
V
L
6
WCE
M
H
Q
Y
P
K
I
A
V
R
D
N
F
G
S
T
L
7
CK
E
W
R
M
P
D
H
Y
Q
N
I
V
T
A
F
G
S
L
8
WHC
Q
P
N
M
D
K
I
Y
G
R
T
E
V
S
F
A
L
9
C
P
D
N
Q
G
E
R
M
T
S
W
K
H
A
I
L
V
F
Y|
0
1
2
|
1
WPDCE
N
Y
H
Q
F
M
G
T
L
S
I
V
A
R
K
2
WPH
E
C
D
R
N
K
Y
G
F
Q
A
M
S
I
T
V
L
3
EW
P
Q
C
T
H
V
K
D
G
R
M
I
N
S
A
L
F
Y
4
CMWHQY
I
N
V
T
F
G
P
R
E
K
L
D
S
A
5
CWMDQHET
P
Y
K
F
N
I
A
G
V
R
S
L
6
CWMDH
E
Q
K
Y
P
N
R
A
F
V
I
G
T
S
L
7
E
D
W
C
H
Q
R
K
N
P
Y
M
G
V
T
A
S
F
I
L
8
WCHM
D
I
Q
E
T
V
N
K
P
Y
R
G
A
S
F
L
9
CWM
P
D
I
T
G
S
N
Q
V
E
F
A
L
H
R
Y
K|
HLA-A*02:01 HLA-A*01:01 HLA-A*03:01
b
it
s
b
it
s
b
it
s
Figure 3.4. Human HLA motifs. The 3 most common HLA types in the
European population. The height of a column of letters is equal to the
information content at that position, whereas the height of each letter within
a column is proportional to the frequency of the corresponding amino acid
at that position [95].
also for the permuted data sets. This strongly indicates that diﬀerences in
amino acid composition between peptides from alternatively spliced normal
and carcinoma transcripts are the driving force of the reduced predicted epi-
tope density. The reason for the observed change in frequency of speciﬁc
amino acids in proteins unique for carcinoma as compared to normal tissue is
unknown, but the phenomenon has previously been observed in studies aim-
ing at identifying biomarkers for early stage detection of cancer: In a recent
study, the levels of alanine, isoleucine, leucine and valanine were found to
be increased in the pancreases of rats with pancreatic cancer as compared to
samples from rats with chronic pancreatitis and healthy rats [23]. In another
study, the levels of N-methylalanine and lysine were found to be signiﬁcantly
increased in the plasma from pancreatic cancer patients, while the level of
glutamine and phenylalanine was found to be decreased [114]. These stud-
ies identiﬁed diﬀerences in amino acid composition in a single cancer type
based on blood plasma and tissue samples. We, in contrast, analyze peptides
unique to cancer in general. As to be expected, the ﬁndings regarding amino
acid concentration reported in this study are not concurrent with those of
the single cancer type studies. A possible explanation as to why we observed
fewer predicted epitopes in peptides, which due to alternative splicing are
uniquely expressed in carcinoma, could be that the host’s immune system
restricts the cancer exome. In that case, pressure from the immune system
disfavors cancer cells that present new epitopes at the cell surface. An alter-
native explanation - which does not exclude the previous explanation - takes
as starting point the observed change in amino acid frequency, especially the
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increase in hydrophilic amino acids in carcinoma proteins. It has been sug-
gested that the stabilization of a protein structure is to a large part due to the
hydrophobic eﬀect [42]. Accordingly, the increase in hydrophilic amino acids
has a destabilizing eﬀect on protein structure, which is in concordance with
the protein loss-of-function that is correlated with cancer progression. This is
exempliﬁed by a study concerning inherited missense mutations of the tumor
suppressor gene, BRCA-1, which may predispose to breast or ovarian cancer
[25]. In this study, it was found that the mutations predominately target con-
served hydrophobic amino acids that are responsible for folding and stability.
Since, in particular, the most common HLA class I allele, A*02:01, prefers
hydrophobic amino acids at the anchor positions, an increase in hydrophilic
amino acids will inevitably lead to fewer predicted epitopes. The reduction in
epitope density in unique carcinoma peptides might therefore be an intrinsic
property of proteins that are destabilized by a decrease of hydrophobic amino
acids as part of the progression to cancer. To our knowledge, this is the ﬁrst
study indicating that alternatively spliced carcinoma transcripts tend to ex-
press fewer potential epitopes than alternatively spliced transcripts found in
normal tissue. The identiﬁed diﬀerence in amino acid composition towards
hydrophilic amino acids in the alternative spliced cancer exome is a possible
explanation for the bias in potential HLA class I epitopes. The preference
for hydrophilic amino acids at the step of alternative mRNA splicing, could
support the development of carcinoma by providing it with the possibility of
evading the host’s immune system. In this case by leading to fewer potential
HLA class I epitopes presented at the cell surface.
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CHAPTER 4. DISCOVERY OF MHAGS ASSOCIATED WITH
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4.1 Introduction
This study presents the analysis of 93 patients that underwent allo-HCT
at the Department of Hematology, Rigshospitalet in Copenhagen. HCT is a
standard treatment for a variety of hematological malignancies. Although pa-
tients are 10/10 allele-matched, small variations in proteins, so-called mHags,
can still cause undesirable immune responses, such as GVHD. Donor reactiv-
ity against patient cells, as induced by mHags, is responsible for GVHD, but
it may also lead to a beneﬁcial GVT eﬀect.
The study is initiated with a comparison to a previous study, followed
by an analysis of gene-speciﬁc correlations to clinical outcome, namely the
separation of genes into those in which it is beneﬁcial or deleterious to have
nsSNPs or mHags. A clear distinction is a prerequisite for identifying mHags
that can be used in therapy. Ideally, one can isolate mHags that trigger the
favorable GVT eﬀect without leading to GVHD. To identify potential mHag
disparities, all patients and donors were genotyped for more than one million
SNPs by a BeadChip Array.
The design of the study was done in collaboration with the Department of
Systems Biology (Thomas Stranzl, Mette V. Larsen, Ole Lund) at the Tech-
nical University of Denmark, the Department of Hematology (Lars Vindeløv,
Bo Mortensen, Brian Kornblit, Henrik Sengeløv) at the Rigshospitalet, the
Department of Biostatistics (Thomas A. Gerds) at Copenhagen University,
and the Department of Health, Immunology and Microbiology (Søren Buus,
Anette Stryhn) at the University of Copenhagen.
4.2 Patients
This study is based on 93 patients and their HLA identical related or 10/10
allele-matched unrelated donor. All patients underwent an allo-HCT with
a peripheral blood graft from their respective donor at the Allo-HCT Lab-
oratory, Department of Hematology, Rigshospitalet in Copenhagen. Donor
selection was based on molecular typing for HLA-A, B, C, DRB1 and DQB1.
All donors were from the same gender as the patients. Patient treatment and
supportive care were done as described in Kornblit et al [48]. All patients were
treated by HCT for a hematologic malignant disease. Out of 93 patients, 35
were treated for acute myeloid leukemia, 19 for chronic lymphocytic leukemia,
24 for non-Hodgkin lymphoma, 11 for myelodysplastic syndrome, three for
myeloﬁbrosis and one for mantle cell lymphoma. 56 patients where male, 37
where female. The median age of the patients at the time of transplanta-
tion was 56 years, the youngest was 31 whereas the oldest was 70. 40 of the
patients had a related donor, the remaining 53 had an unrelated donor.
4.3 Genotyping
Illumina´s four-sample HumanOmni1-Quad BeadChip Arrays were used for
determining the genomic variation of the 93 leukemia patients, as well as
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their respective donor. The BeadArray delivers genome-wide coverage and
covers more than one million markers. These markers, covering SNPs and
CNVs, are based on published disease associate studies, all three phases of the
International HapMap Project as well as markers from the 1,000 Genomes
Project. The BeadArray is based on the human genome build NCBI 36.2,
USCG hg18. Genotyping and data preparation was done by AROS Applied
Biotechnology AS, Aarhus, Denmark. On average, there were 1,006,041 SNPs
(+- 36,165 SD) successfully genotyped per sample.
4.4 Identiﬁcation of nsSNPs diﬀering in Graft vs Host
direction
All SNP diﬀerences per patient-donor pair were extracted. Only SNPs suc-
cessfully identiﬁed by genotyping in both the patient and the donor were
taken into account. On average, 303,057 (+- 77,123 SD) SNPs diﬀered per
patient-donor pair. Per SNP, gene name, protein name and amino acid se-
quence were extracted from Ensembl build 54_36p. A SNP’s eﬀect on the
transcript and further the amino acid sequence were determined by use of the
Ensembl-api [86]. SNPs present on the Illumina HumanOmni1-Quad Bead-
Chip Array are biallelic and listed with respect to their TOP/BOT strand
designation; in addition, Illumina lists alleles in accordance with forward
orientation of dbSNP. Strand designation is, however, not consistent with
forward/backward orientation from Ensembl. Therefore, both nucleotides
per SNP as well as the respective reverse complement were queried against
Ensembl. A SNP is deﬁned as protein coding if 1 of the 4 nucleotides at a
given chromosome and position is consistent with the nucleotide leading to
a reference protein from Ensembl. If Illumina´s forward allele is linked to a
reference protein, then Illumina´s strand information is in accordance with
Ensembl. If, however, the reverse complement is linked to a reference protein,
then Illumina´s strand is, compared to Ensembl, reversed. Based on this, Il-
lumina SNPs were ﬂagged to be in accordance with Ensembl. This approach
is successful if dealing with non-ambiguous SNPs. Ambiguous SNPs (A/T
and C/G SNPs) would, if they are protein coding, match as given and as their
reverse complement. Within our dataset, we have 12.3% ambiguous SNPs.
Strand information relative to Ensembl for ambiguous SNPs was obtained by
blasting the probe sequence against the human genome NCBI build 36.2. The
matched strand was assigned if there was a clear match on only one strand.
Overall, we identiﬁed 20,036 unique SNPs with a varying genotype in at least
one patient-donor pair. A subset of 17,580 SNPs were non-ambiguous SNPs.
We could assign reliable strand to additional 1,673 SNPs, whereas 783 SNPs
where removed from the data set. Most of the on average 303,057 SNPs
diﬀering between patients and their donors are either in non-coding regions
or do not alter the amino acid sequence of the coded protein. An mHag
presumes a change in amino acid sequence, therefore we extracted the subset
of non-synonymous coding SNPs (nsSNPs) with correctly identiﬁed strand
of the previously identiﬁed SNP diﬀerences. On average, there are 4,922 (
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1,348 SD) nsSNP diﬀerences per patient-donor pair. A nsSNP must diﬀer
in GvH direction for being considered as a potential mHag. The removal of
nsSNPs not diﬀering in GvH direction resulted in a new set of 2,748 (mean,
 825 SD) nsSNPs in GvH direction per patient-donor pair.
4.5 Identiﬁcation of potential mHags
Minor histocompatibility antigens (mHags) are epitopes raising an immuno-
logical response in some organ transplants. Each of the above identiﬁed nsS-
NPs in the Graft vs Host direction could lead to potential mHags of interest.
For each nsSNP diﬀerence in GvH direction, the binding of the peptide con-
taining the SNP was assessed using NetMHCpan 2.4 [35]. 9-meric peptides
were used as possible binders, as most peptides binding to MHC class I con-
sists of 9 amino acids [59]. Two possible nucleotides for a nsSNP result in
two protein sequences diﬀering by one amino acid. For each possible amino
acid per nsSNP, there are 9 unique 9-mers, with a varying position of the
unique amino acids from one to nine within the 9-mer. Per donor-patient
pair, the binding predictions were applied to the patients HLA-A, -B and -C
molecules on the unique 9-mers occurring in the patient. As a patient has
up to six diﬀerent alleles and 9 possible 9-meric mHAgs per SNP, the num-
ber of predicted 9-meric mHAgs for a speciﬁc binding strength threshold can
vary from zero per SNP to more than one per SNP. With a binding strength
threshold of 1% (binding strength falling within the top 1% compared to a
large set of random natural peptides) the average number of potential mHags
in the GvH direction per patient-donor pair is 790 ( 267 SD).
4.6 Comparison to previous study
In a previous study by Larsen et al. [51], an impact on overall survival based
on the number of nsSNP and mHags was shown. Patients with fewer nsSNP
disparities with their donor and subsequent with fewer predicted mHags had a
better survival rate than patients with many nsSNPs disparities and predicted
mHags. The study was based on 126 patients who underwent allo-HCT. SNPs
in this study were identiﬁed without high-throughput methods; only SNPs
within genes with known minors were studied.
The study by Larsen et al. is partly based on the same patient set as the
93 patients that were genotyped with the HumanOmni1-Quad BeadChip Ar-
rays. The two studies have 73 patient-donor pairs in common. In the study
by Larsen et al. 96 SNPs were genotyped per patient-donor pair. The selec-
tion of SNPs for the study was based on proteins known to contain mHags.
Eleven non-Y chromosomal proteins with known mHags were selected from
the dbMinor database [106]. Although the genotyping approach using the
BeadChip Array covered more than one million SNPs, only 33 of the pre-
viously genotyped SNPs were included. In the 73 patient-donor pairs that
overlapped between the two studies, these 33 SNPs were identiﬁed identically
by the two genotyping approaches.
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Gene nsSNPs occurence
AKAP13 16 348
BCL2A1 3 76
C19orf48 2 34
CENPM 1 23
CTSH 2 24
HMHA1 3 61
HMHB1 1 16
KIAA0020 2 4
MYO1F 1 1
MYO1G 2 41
SP110 9 194
TOR3A 1 28
TYMP 1 10
Table 4.1. Selected genes with known mHags. The table lists 13
genes with known mHags, where we observed nsSNP-variation in the GvH
direction. Genes in bold are the subset of genes in common with the study by
Larsen et al. [51]. The number of nsSNPs in the GvH direction for each gene
is shown. Occurrence is deﬁned as the number of nsSNP disparities observed
per gene over all 93 patient-donor pairs.
Genes with known mHags
In order to analyze a comparable subset of SNPs and mHags, in addition
to all SNPs covered by the BeadChip Array, we made a similar selection of
SNPs as Larsen et al. Genes were selected based on dbMinor. As these genes
have been found to contain mHags, they are of interest in the context of
hematopoietic cell transplantation. Based on dbMinor, there are 14 non Y-
chromosomal genes with known mHags. Two additional genes (C19orf48 and
MYO1F) were extracted from [104]. 13 out of these 16 genes had nsSNPs in
the GvH direction in our patient-donor set (see Table 4.1). In addition, the
number of unique SNPs expressed within these genes is shown. The six genes
listed in bold are also included in the analysis of Larsen, whereas the other
7 genes are only included in our study. The previous study excluded these
genes (as well as C19orf48 and MYO1F) as the patient-donor pairs analyzed
did not display SNP variation for these genes.
Related and unrelated donor separation
Within our data set of 93 patient-donor pairs, 40 of the patients had a
matched related donor (MRD) and 53 had a matched unrelated donor
(MUD). In the study by Larsen et al., the number of nsSNPs in the GvH
direction was comparable between MRDs and MUDs as shown in Figure 4.1
A. In the presented study, we analyze far more SNPs per patient and a clear
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Figure 4.1. Histogram of nsSNPs in related and unrelated patient-
donor pairs. Both plots display the distribution of nsSNPs in GvH di-
rection. Plot A shows the distribution of analyzed nsSNP diﬀerences for
MRD and MUD patient-donor pairs based on the study by Larsen et al. [51].
The distributions for the two groups in this study were roughly equally dis-
tributed. Our data (plot B) displays, based on the number of nsSNPs, a clear
distinction between MRDs and MUDs.
separation between the numbers of nsSNPs in the GvH direction for MRDs
versus MUDs become apparent. Figure 4.1 B shows that related and unre-
lated pairs have their own distribution of nsSNPs. Related donors are clearly
separated from unrelated donors with regards to the number of SNPs. In
the study of Larsen, patients were splitted into diﬀerent cohorts based on the
number of observed nsSNP and mHag diﬀerences. In the presented study,
a similar separation of donor-patient pairs by the number of nsSNPs would
just be a separation in related vs. unrelated donors. For the correlation of
the number of predicted mHags with overall survival (OS), we have therefore
chosen to analyze MRDs and MUDs separately.
Overall survival analysis
Larsen et al. observed a non-signiﬁcant higher OS for patients with fewer
nsSNP diﬀerences in the GvH direction than patients with more nsSNP dif-
ferences (Figure 4.2A). Applying the same analysis on predicted mHags
instead of on nsSNPs boosted the diﬀerence in OS between patient-donor
pairs with few versus many predicted mHags. Patients with few predicted
mHags were shown to have a signiﬁcantly higher OS than patients with many
predicted mHags 4.2B).
In the present study, we applied a log-rank test, based on the number of
observed nsSNP or mHags diﬀerences, to estimate the association between
the number of observed diﬀerences and overall survival. To minimize the
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eﬀect of diﬀerent follow-up lengths for diﬀerent patients, the follow up time
of all patients was set to 1000 days. Related and unrelated matched donor
pairs were analyzed separately. Limiting our OS analysis to the 6 genes in
common with the study by Larsen, we ﬁnd the same tendency for MRD
patients as Larsen et al. For the graphical representation, patient-donor
pairs were divided by the median of nsSNP or mHag diﬀerences. As shown
in Figure 4.3 we observed a comparable diﬀerence between MRD patients
with few/many predicted mHags and few/many nsSNPs. Calculated p-values
are not signiﬁcant; in contrast to Larsen et al. our p-value is calculated on
overall survival only, it is based on a smaller set of patient-donor pairs, and
does not integrate other factors.
Each analysis was further done on the whole set of genes and on the
subset of genes with known mHags. No diﬀerence in overall survival was
observed for MUD patient-donor pairs. For the MRD pairs, we could identify
tendencies, but the observed diﬀerences were not statistically signiﬁcant (data
not shown). Investigating nsSNP diﬀerences in the GvH direction resulted in
a lower p-value (p=0.059) when analyzed for genes with known mHags only,
as compared to all genes (p=0.244). The tendency of fewer nsSNPs being
correlated with a higher OS is given, but only when we limit the analysis to
genes with known mHags (Figure 4.4. Correlating OS with predicted mHags
instead results in the same tendencies, reported p-values are, however, higher.
Based on our results, we could identify some tendencies, but we could not
reproduce the ﬁndings by Larsen et al. that the diﬀerence in OS is more clearly
correlated to the number of predicted mHags than to the number of nsSNP
diﬀerences. Our patient cohort is not independent from the cohort analyzed
in the other study, but our sample size is. Due to overall fewer patients
and the further split in MRDs and MUDs, it is considerably smaller. Since
we could not observe an improvement when using the number of predicted
mHags as a predictor for OS instead of the number of nsSNPs, we did all
subsequent analyses based on both nsSNP and mHag diﬀerences.
Although we could not reproduce the results by Larsen et al., we are not
stating that adding predictions of mHags is not resulting in a stronger sig-
nal than nsSNPs disparities alone. Instead, we suggest that the gene that
contains the nsSNP or mHag is an important factor that must be taken into
account. It is hence likely that nsSNP disparities and mHags in some genes
will lead to elevated levels of GVHD and lower OS, while nsSNP disparities
and mHags in other genes preferably will lead to GVT and hence higher
OS [7]. This separation could for instance be based on the tissue expression
of the gene in question: nSNPs and mHags in genes that are preferentially
expressed in hematopoietic tissues would result in GVT eﬀects without dele-
terious GVHD, because the GVHD elicited by such mHags would only result
in the removal of normal recipient hematopoiesis. In contrast, nsSNPs and
mHags with a broad tissue expression would carry the risk of inducing po-
tentially life-threatening GVHD. By chance, the nsSNP disparities in the set
of patient-donor pairs analyzed by Larsen et al. are distributed in such a way
that it was possible to observe an improved predictive performance on OS
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when using mHags rather than nsSNPs. In another set of patient-donor pairs
and in particular when including nsSNPs in other genes, this improvement is
lost, since nsSNPs and mHags in some genes will lead to GVHD and lower
OS, while they in other genes lead to GVT and higher OS. It is the aim of
this study to try to identify these sets of genes in which it would be, respec-
tively, beneﬁcial and deleterious for the patients to have nsSNP disparities
and mHags.
4.7 Gene-speciﬁc analysis
Modeling disease course
Based on disease progression data for each patient, we modeled the disease
course of patients after HCT. An association of genes with OS alone would
be less suﬃcient, as patients could for example die, as a direct consequence
of relapse, or die of because of other reasons.
We analyzed the time from the day of transplant to an event. The follow-
ing events were considered: relapse or relapse related death, acute GVHD,
and chronic GVHD (see Figure 4.5. Patients with grade I acute GVHD were
considered as not aﬀected by acute GVHD.
Association analysis
We analyzed the association of the genotype (number of SNPs/number of epi-
topes) and the cause-speciﬁc hazards of the events acute and chronic GVHD
by censoring patients who died at their time of death. To analyze the associa-
tion of genotype and the cause-speciﬁc hazard of relapse we considered death
due to relapse as events and censored only patients who died in remission.
We analyzed the cause-speciﬁc parameters and not the cumulative inci-
dences because the latter also reﬂect the rates of the events of the competing
events, and we were only interested in the biological mechanism that drives
the risk of an event. See Kahl et al. [39] for a similar argument.
For each of the three time-to-event responses, the nsSNP diﬀerences and
potential mHags were analyzed separately. Overall, we had 9,162 genes where
one or more patient-donor pairs had at least one nsSNP diﬀering in Graft vs.
Host direction. The prediction of potential mHags resulted in a reduced set
of 6,359 genes.
For the most interesting genes, all or the great majority of patients who
relapsed (respectively had acute or chronic GVHD) had the same genotype:
If they had negative genotype (zero SNPs or zero predicted mHags) then this
gene is a candidate protective gene. If they had positive genotype (at least
one SNP or one predicted mHag) then this gene is a candidate risk gene.
It is important to note that for these genes, where e.g. all observed events
occur in patients with concurrent genotype, a univariate or multivariate Cox
regression model cannot be estimated, as there are no events in one of the
genotype groups. For the same reason, GVHD could not be considered as
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Figure 4.2. nsSNPs and predicted mHags as possible markers for
overall survival. Diﬀerence in overall survival for patients with few/many
nsSNPs/mHags as shown by Larsen. The number of predicted mHags (B)
is a better marker for overall survival than the number of observed nsSNPs
(A).
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Overall survival - 6 genes
(nsSNPs, 6 genes, MRD, P=0.093)
(mHags, 6 genes, MRD, P=0.264)
A
B
Figure 4.3. Probability of overall survival for nssNPS and mHags,
based on 6 genes. Analysis based on genes in common with the study by
Larsen et al. Selected genes are known to encode mHags. Plot A is based
on nsSNP diﬀerences for matched related patients, plot B shows the ana-
lysis based on predicted mHags. P-values are based on log-rank tests with
the number of observed nsSNP/mHag diﬀerences as predictors. The black
line shows the survival probability for patients with fewer observed diﬀer-
ences. The legends list the cutoﬀs for separating patients into groups based
on number of nsSNP/mHags diﬀerences. Shaded areas are the conﬁdence
intervals.
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Overall survival - nsSNPs
(nsSNPs, all genes, MRD, P=0.244
(nsSNPs, genes w. known mHags, MRD, P=0.059
A
B
Figure 4.4. Probability of overall survival based on observed nsSNP
diﬀerences. Plots are for matched related donors. Plot A is based on
all nsSNP diﬀerences in GvH direction, as identiﬁed by our study. Plot B
includes only nsSNPs from 13 genes (see Table 4.1), namely genes known to
express mHags.
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Figure 4.5. Multi-state model for the possible temporal courses of a patient
after transplantation. The arrows describe the transitions from one state
to another, and the arrow labels the number of patients with an observed
transition.
a time-dependent confounder for the estimation of relapse hazards. Thus,
paradoxically, in our analysis, the fact that the Cox model does not converge,
makes the corresponding gene interesting. Therefore the genotype-hazard
associations were analyzed with the log-rank test.
In the light of the small sample sizes and small numbers of events we
decided not to trust the asymptotic approximation of the log-rank statistic
and to obtain exact p-values. For calculating an exact p-value for all genes,
the associated responses for each patient-donor pair were permutated 10,000
times. The observed log-rank test statistics where then compared to the
distribution of the permutated log-rank statistics which should resemble the
null hypothesis. Note that with 10,000 permutations the smallest possible
exact p-value is 0.0001.
For each time-to-event response and separately for nsSNP and the poten-
tial mHags, all genes were ranked according to the exact log-rank p-values.
For the nsSNPs analyses and with a p-value < 0.05 there are 417 relapse-
associated genes, 467 genes are associated with acute GVHD, and 418 genes
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Event Genotype 0 Genotype >0
Censored 57 0
Relapse 15 2
Other event 19 0
Probability of relapse 0.165 1
Table 4.2. Example for calculating the relapse risk. The fraction of
patients that had experienced relapse among all the patient-donor pairs is
calculated for both patient-donor pairs with and without predicted mHags.
For the given gene, with an increased number of mHags diﬀering between
patient and donor, we would have an increased risk of relapse. Patients
associated to Genotype 0 have no predicted mHag variation for the analyzed
gene. Patients with Genotype > 0 have, for the gene in question, at least one
predicted mHag diﬀerence to their donor.
are associated with chronic GVHD. The mHags analyses report 213 genes for
relapse, 348 for acute GVHD, and 276 genes associated with chronic GVHD.
Note that p-values are not corrected for multiple testing. After correction for
multiple testing (Bonferroni-Holm), there are no signiﬁcant genes. The num-
bers of signiﬁcant genes for nsSNPs and mHags are not directly comparable,
as genes with potential mHags are only a subset of the genes with nsSNPs
and the number of associated patient-donor pairs associated per endpoint
varies.
Genes can either be positively associated (i.e. the more nsSNPs or mHags
the higher the risk of the event) or negatively associated (i.e. the less nsSNPs
or mHags the higher the risk of the event) to the event hazard. Based on
the distribution of observed events, genes were marked as either positively
or negatively associated within each list. In the case of relapse and potential
mHags, this was done by calculating the fraction of patients that had expe-
rienced relapse among all the patient-donor pairs with no predicted mHags
in the speciﬁc gene. Likewise, the fraction of patients with relapse among
all the patient-donor pairs with predicted mHags, were calculated. A higher
fraction of relapse in patient-donor pairs with more than one mHag is equiv-
alent to an increased risk of relapse with an increased number of mHags.
Similarly, a decreased relapse rate with an increasing number of mHags is
given if the fraction of patients with relapse is higher for patient-donor pairs
with no diﬀerence in amount of mHags. An example is shown in Table 4.7.
Table 4.7 shows the number of genes with a p-value < 0.05 contributing
either to increased or decreased hazard for each endpoint. Overall, for each
group we identiﬁed more genes associated with increased risk as compared
to decreased risk. An exception is the association of relapse with having
more nsSNPs. Here, we found more genes to be associated with decreased
risk. Assigning all 9,162 genes with nsSNP variation as well as all 6,359
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Type Event Associated risk Genes p-val < 0.05
nsSNPs
relapse increased 122decreased 295
aGVHD increased 369decreased 98
cGVHD increased 306decreased 112
mHags
relapse increased 176decreased 37
aGVHD increased 337decreased 11
cGVHD increased 225decreased 51
Table 4.3. Classiﬁcation based on risk. For each endpoint, the num-
ber of genes with a p-value < 0.05, associated with either an increased or
decreased risk, is given. P-values are not corrected for multiple comparisons
and group sizes are not directly comparable.
genes with mHag variation in both cases resulted in a 2-2.5 times larger set
of genes associated with decreased risk. The data shows that within the
set of genes possibly associated with relapse, there is a higher likelihood for
the nsSNPs set to be signiﬁcantly associated then compared to the mHags
set. Per analyzed endpoint, the top 10 ranking genes, where an observed
diﬀerence in number of mHags is positively or negatively associated with
the respective endpoint, are shown in Tables 4.7, 4.7 and 4.7. None of
the p-values are signiﬁcant after correction for multiple testing (Bonferroni-
Holm). Interestingly, AKAP13 is the top three ranked gene in the ranked
gene-list associated with decreased relapse. The gene is a known source of
mHags [105]. AKAP13 has, due to its length, many possible sources for SNP
mismatches. For other genes with known mHags, as listed in Table 4.1, we
could not see any clustering of these within our ranked gene-lists. The top
10 ranked genes per endpoint, identiﬁed by analyzing nsSNP disparities, are
listed in the Appendix.
The cumulative incidence over 5 years, for the top ranked gene based on
the mHags analysis, are shown in Figure 4.6 and Figure 4.7. Per plot, two
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cumulative incidence curves are shown: one for patient-donor pairs with no
mHag disparities for the given gene, and one for patient-donor pairs with one
or more mHag disparities for the gene in question. For the three analyzed
endpoints, the cumulative incidences, for the top ranked genes positively
associated with the risks, are shown in Figure 4.6. Here, patient-donor
pairs with mHags disparity have an increased risk of the event. Cumulative
incidence plots for the top genes associated with decreased risk are shown in
Figure 4.7. Patient-donor pairs with mHag disparity have a decreased risk
of the respective event.
4.8 Overlap analysis
Based on our ranked gene lists, higher ranked genes are more likely corre-
lated with the respective outcome. One obvious question is, if the same sets
of genes are shown to be involved in diﬀerent endpoints. To investigate this
we analyzed the observed overlap of the top ranked genes from each list. The
expected overlap and standard deviation between two groups was calculated
by random sampling (10,000 permutations) from the respective groups. Ob-
served overlaps as well as expected overlaps between the 300 top ranked genes
of all groups are shown in Figure 4.8. This cutoﬀ was chosen, as observed
numbers are easy to interpret. The results do not change if other cutoﬀs, such
as genes with a p-value < 0.05 or the top 5% of each ranked gene list, are
used. Data shown in Figure 4.8 illustrates that, depending on the endpoint,
some gene sets have more and some less genes in common that expected from
random sets of equal size. As expected, the top 300 ranked genes for the same
endpoints, but associated with either with nsSNPs or mHags diﬀerences, al-
ways share more genes as compared to random. Out of 300 genes, for all 6
endpoints there is an overlap between 68 and 89 genes. While this overlap
is larger than random, it shows that analyzing predicted mHags based on
nsSNPs, instead of analyzing nsSNPs directly, does result in varying gene
lists. Due to the design of the study, there are no overlapping genes for
each comparison, where the endpoint is only diﬀering by the association of
the genes to an increased or decreased likelihood of the respective event. Of
special interest, with possible further applications for therapy, is the identi-
ﬁcation of genes uniquely associated with a GVT eﬀect. Chronic GVHD and
GVT often occur together and an actual overlap could be expected. Con-
sidering our analysis based on nsSNPs, we found a signiﬁcant lower overlap
between decreased relapse (GVT) and increased acute GVHD. This signal
is, however, lost, if we take the respective overlap of ranked genes based on
mHag diﬀerences. Based on our analysis of mHag diﬀerences for the top 300
ranked genes, there are two endpoints with a signiﬁcant (mean  2 SD)
overlap. First, decreased relapse has more than expected genes in common
with decreased acute GVHD. While a possible explanation seems far-fetched,
there is a special interest in genes both associated with a GVT eﬀect and a
decrease of GVHD, as both have a favorable eﬀect for a patient. The second
signiﬁcant correlation is a negative correlation, where the observed overlap
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Figure 4.6. Cumulative incidences for positively associated event
hazards. The cumulative incidence is the probability that the given event
has occured before a given time. Plots are based on the top ranked genes
of the respective gene list. The more mHags, the higher the risk of the
given events. The plot “relapse - increased risk” is interpreted as follows:
81 patient-donor pairs had the same genotype for the given gene, while 12
patient-donor pairs had a mHag disparity of at least one mHag. The 12
patients with mHag disparity to their donor have a higher hazard of relapse
as compared to patients with no mHag disparity. The shaded area is the
conﬁdence interval.
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Figure 4.7. Cumulative incidences for negatively associated event
hazards. The plots show the cumulative incidences, for the respective top
ranked gene per genelist associated with mHags disparities, for the ﬁrst ﬁve
years. The plot “relapse - decreased risk” is interpreted as follows: 66 pa-
tients without mHag disparity to their respective donors have a higher hazard
of relapse as compared to patient-donor pairs with mHag disparity. In other
words, patient-donor pairs with mHag disparity have a lower likelihood (de-
creased risk) of relapse as pairs with the same genotype.
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is smaller than the expected overlap. Here, genes associated with increased
relapse are shown to have a smaller overlap than expected to genes associated
with increased chronic GVHD. While both eﬀects are unwanted, it is diﬃcult
to explain, why a gene would be associated with an increased possibility of
relapse. In relation to relapse, mHags could only be associated with a de-
creased risk of relapse, as these mHags are playing a role in a possible GVT
eﬀect. A SNP diﬀerence may however up or down regulate the expression
of gene or aﬀect a proteins function. This change could further lead to an
increased likelihood of relapse. Overall, our analysis seems to indicate, that
there is no particular tendency of genes being positively or negatively corre-
lated to either acute or chronic GVHD. On the contrary, for relapse, there
are usually either more or less genes, than compared to random, associated
with both acute and chronic GVHD.
4.9 Tissue expression analysis
Acute GVHD is not damaging all of a patient’s tissues, it primarily occurs
in liver, skin and the gastrointestinal tract [19]. While chronic GVHD is
attacking these tissues too, it is shown to be more widespread than aGVHD.
Favorable mHags contributing to a Graft vs. Leukemia eﬀect, on the other
hand, are largely limited to hematopoietic tissues. One of the challenges is the
segregation of potential GVT eﬀects from GVHD. Minor histocompatibility
antigens with expression largely limited to hematopoietic tissues are shown to
be able to treat hematologic malignant diseases without GVHD [96]. Based
on this, we hypothesized that genes associated with the GVT eﬀect are more
commonly expressed in hematopoietic tissues. Genes associated with acute
and chronic GVHD, while they might be expressed in hematopoietic tissues
too, might be highly expressed in tissues such as liver and skin. In order to
investigate these assumptions, we analyzed our gene lists for diﬀerences in
tissue expression.
In order to test these assumptions, we compared the mRNA expressions
of the top ranking genes of our analyzed endpoints. First, we analyzed diﬀer-
ences in mRNA expression for hematopoietic tissues, and liver and skin. This
analysis, based on the GNF gene expression database [109]. A variation in
tissue-speciﬁc expression for the diﬀerent endpoints was expected, we could
however not identify any variations in mRNA expression (see Appendix). An
alternative approach to investigate tissue expression is based on the Human
Protein Reference Database (HPRD) [44]. The database (release 9) covers
protein expression for 578 diﬀerent tissue types, extracted from literature.
The 300 top ranked genes associated per endpoint were compared against a
pool of 300 random sampled genes. The random sampling was done 10,000
times; the genes were sampled out of all 9,162 genes associated with nsSNP
diﬀerences. The number of genes associated with each tissue type was cal-
culated per analyzed endpoint. Per tissue, an exact p-value was calculated
based on how many times more genes were associated with the respective tis-
sue, as compared to the 10,000 random permutations. Tissues signiﬁcantly
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associated with decreased likelihood of relapse and increased risk of acute &
chronic GVHD are shown in Figure 4.9. Observed diﬀerences are not signif-
icant after correction for multiple comparisons. For decreased risk of relapse
(mHags analysis) and three hematopoietic tissues (hematopoietic stem cell,
lymphoid stem cell, myeloid stem cell), we found the 300 top ranked genes to
be overexpressed, as compared to random. While this is consistent with our
expectations of GVT being associated with hematopoietic tissues, we could
not ﬁnd any expected correlations for other endpoints. Further, we found the
top ranked genes correlated with unexpected tissues (as deﬁned by HPRD
database), such as hair and milk.
4.10 Conclusion
In this study we investigated a gene-speciﬁc association between the number
of nsSNPs or predicted mHags and possible temporal courses of 93 patients
following allo-HCT. All patients and their respective donor were genotype by
a BeadChip Array. Per patient-donor pair, nsSNPs disparities in the GvH
direction were identiﬁed and, based on these, mHags were predicted. The
patient set is partly coherent with the set used in the study by Larsen et al.
However, while we analyzed genome-wide diﬀerences, the study by Larsen et
al. only analyzed 11 genes known to contain mHags.
By analyzing our data set in a similar way as to the study by Larsen, we
could not reproduce their ﬁndings. This might be due to a signiﬁcant smaller
data set. Based on a diversiﬁcation of observed nsSNP diﬀerences for related
and unrelated donors, we had to further split our, from the beginning already
smaller, dataset. Limiting our analysis to genes known to contain mHags
resulted in a stronger signal than an analysis based on all genes covered by
the array. This indicated that gene-speciﬁc distinctions for the eﬀect of a
nsSNP or mHag exist.
We deﬁned three time-to-event responses, namely relapse, acute GVHD
and chronic GVHD. For each of these temporal endpoints, an association for
each gene covered by the analysis was done. Ranked gene-lists associated to
each of these events, based on 10,000 permutations and log-rank tests were
generated for observed nsSNP and mHag diﬀerences. Based on the distribu-
tion of observed events, genes were either positively or negatively associated
to the event hazard. While the ranking of genes is correlated to their sig-
niﬁcance for each endpoint, no p-values were signiﬁcant after correction for
multiple testing.
An analysis of the overlap of the respective top ranked genes from each
group was performed. For clinical application, genes associated with GVT
(decreased relapse) and not associated with increased acute or chronic GVHD
are of signiﬁcant interest. Based on our analysis, such genes could be identi-
ﬁed and they could be subsequent tested for potential mHags.
Tissue expression of mHags is believed to play a role for the GVT eﬀect.
These favorable mHags are expressed in hematopoietic tissues, as this en-
ables them to support tumor eradication. In contrast, acute GVHD occurs
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Figure 4.9. Genes per tissue types. Signiﬁcant tissue types, where the
300 top ranked genes are overexpressed as compared to all analyzed genes,
are shown. Gene lists associated with shown endpoints are based on the
mHags analysis. Expression information is based on Human Protein Refer-
ence Database. Observed number of expressed genes (out of 300 top ranked)
for the three shown endpoints is given by the blue bar. The expected number
of genes per tissue type (grey bar) is deﬁned by the mean of 10,000 random
samples of 300 genes. Random sampling is based on all 9,162 genes with
nsSNP diﬀerences. Data is not normalized. Error bars represent the SD of
the random samples.
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primarily in liver, skin and the gastrointestinal tract and chronic GVHD is
shown to aﬀect more tissues. For our top ranking genes, we investigated their
overexpression in diﬀerent tissue types. We could not ﬁnd any signal based
on mRNA expression data, but we could, based on HPRD database, identify
a potential overexpression of genes associated with GVT in hematopoietic
tissues.
Our ranked gene lists associated with event hazards are of potential im-
portance when testing predicted mHags in the laboratory. Experimental ver-
iﬁcation of mHags is a time consuming process and a pre-selection of potential
source-genes is desirable. While we could not identify signiﬁcant p-values af-
ter correction for multiple testing, we believe that the ranking of genes based
on observed p-values is still valuable. A larger data set would have enabled
a more speciﬁc analysis of the diﬀerent temporal endpoints. In our study,
we had to deal with a relatively heterogeneous patient set of related and
unrelated donors and diﬀerent hematopoietic malignant diseases. The use
of immunosuppression for treatment is another possible restriction. While
grade IV acute GVHD is per deﬁnition fatal, grade II and III are treated by
heavy immunosuppression. This would, however, also oﬀset any GVT eﬀect
by the immune system. The other possible GVHD is chronic GVHD. It is
assumed that mHags leading to chronic GVHD are associated with a GVT
eﬀect. Patients can have acute GVHD without subsequent chronic GVHD,
or vice versa.
Each patient-donor pair has mHags with favorable as well as with un-
desirable eﬀects. A mix of these beneﬁcial and mHags results in conditions
that are a mix of the above mentioned conditions. This makes it diﬃcult
to pinpoint speciﬁc genes being associated to speciﬁc temporal endpoints.
Given a more homogenous data set or large enough sample size, this should,
however, be possible. In this study we could identify, for each event, genes
being more correlated than others genes. These ﬁndings are planned to be
used for subsequent mHag identiﬁcation at the Department of Hematology,
Rigshospitalet in Copenhagen.

Chapter 5
Concluding remarks
In this thesis I have presented and discussed applications of cytotoxic T cell
epitope predictions. First, I present a MHC class I pathway epitope predic-
tor, NetCTLpan. Presently, we observe a growing interest in epitope based
vaccine design, and at the same time high-throughput genome sequencing is
becoming increasingly available [92]. Methods for experimental validation of
T cell epitopes are time-consuming and allow only for testing of antigens that
can be puriﬁed in large enough quantities [82]. Methods for the prediction of
T cell epitopes are shown to minimize experimental eﬀorts needed to identify
new immunogenic peptides. These methods are part of the reverse immunol-
ogy concept: after the selection of candidate genes, potential immunogenic
peptides are predicted, with subsequent experimental validation. With the
availability of high-throughput genome sequencing, the number of predicted
epitopes can be huge. In this setting, NetCTLpan could be used to select a
more promising subset of peptides for experimental validation.
While epitope prediction optimized for a low false positive rate is beneﬁ-
cial for the identiﬁcation of new immunogenic peptides, reverse immunology
approaches could also be applied, when classical approaches would be prob-
lematic due to diﬃculties in cultivating certain pathogens. Another applica-
tion is presented in Part III of this thesis. The project utilizes NetMHCpan for
the prediction of potential epitopes on a large scale. This predictor was used,
as our goal was not the identiﬁcation of new epitopes, but we were interested
in observed epitope densities in diﬀerent sets of proteins. We found that pep-
tides unique to cancer splice variants comprise signiﬁcantly fewer HLA class I
epitopes compared to peptides unique to normal transcripts. While cancer is
known to employ mechanisms to escape immune surveillance, such as dysreg-
ulating pathways and downregulating HLA expression, we presented a ﬁrst
report that carcinoma has a bias towards displaying fewer epitopes, which is
initiated already at the step of mRNA splicing. A possible explanation could
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be that the host´s immune system restricts the cancer exome. We found fur-
thermore that hydrophilic amino acids are signiﬁcantly enriched in the unique
carcinoma sequence. This contributed to the lower likelihood of carcinoma-
speciﬁc peptides to be predicted epitopes, as an increase in hydrophilic amino
acids has a destabilizing eﬀect on protein structure. In particular, the most
common HLA class I allele, A*02:01, prefer hydrophobic amino acids at the
anchor positions. Therefore, we expected fewer predicted epitopes with an
increase of hydrophilic amino acids. This explanation does not exclude the
possibility of the host´s immune system restricting cancer cells, by eradicating
cancer cells that present new epitopes in complex with MHC. Treating cancer
with epitope-based vaccines is a challenging ﬁeld and despite many eﬀorts,
their use has not advanced beyond phase I or II clinical trials [119]. More
knowledge of the immunology involved in cancer immunotherapy is needed;
the presented work contributes to a better understanding of the mechanisms
leading to cancer-speciﬁc epitopes.
The focus of the third project described in this thesis is on the role that
nsSNPs and mHags play in transplantations. In the context of transplanta-
tions, mHags are epitopes unique to the patient. The donor´s transplanted
immune cells classify these epitopes as foreign and mediate an immune re-
sponse. This reactivity against patient cells is responsible for GVHD, a dis-
ease that, depending on the grade, requires pharmacologic immunosuppres-
sion. While GVHD is undesirable, some mHags may also lead to a beneﬁcial
GVT eﬀect. Beneﬁcial mHags were previously shown to be restricted to
hematopoietic tissues. That is, as this enables the donor´s grafted immune
cells to raise an immune reaction against diseased cells of the hematopoietic
system of the host. GVHD is usually observed in liver, skin, the gastrointesti-
nal tract, or in the connective tissue. Ideally it should be possible to identify
mHags, which do not lead to GVHD, as they are restricted to hematopoietic
tissue, and can aid in curing the patient for his malignancy, or at least lower
relapse related mortality (RRM) and improve OS. The purpose of our study
was to separate genes into those in which it is beneﬁcial vs. deleterious to
have nsSNPs or mHags. While a distinction of mHags into beneﬁcial or un-
desirable eﬀects seems reasonable, a classiﬁcation of SNPs into these groups,
based on an immunological response, is questionable. A SNP is only a possi-
ble target for the immune system, if it is part of a peptide that is presented
in complex with MHC at the cell´s surface. While a SNP can be associated
with disease progression due to other factors, such as regulation of pathways,
we still expect to see a weak signal when looking at SNPs alone. That is, as
a SNP in a gene that is preferentially expressed in hematopoietic tissue, may
be part of a presented peptide associated with a GVT eﬀect. On the other
hand, the SNP might be indiﬀerent. That is given, if the SNP is not part of
a presented peptide. Adding predictions of which SNPs are potential mHags
should strengthen the signal, since we remove indiﬀerent SNPs.
A clear distinction of genes associated with beneﬁcial or deleterious nsS-
NPs or mHags to temporal courses after HCT is valuable for subsequent
experimental mHag identiﬁcation. Based on our ﬁndings, we can give a ten-
dentious association per gene, based on the number of observed nsSNP or
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mHag disparities, to three temporal courses following HCT, namely relapse,
acute GVHD and chronic GVHD.
All three studies taken together give new insights about the immune sys-
tem and how it interplays with cancer, which brings us closer to an under-
standing of how epitopes could be used for cancer therapy.
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Appendix
Tissue-speciﬁc mRNA expression levels
Expression data from the GNF gene expression database [109] covers mRNA
data on 79 human tissues. The data was normalized using robust multi-array
averaging (RMA) and bias corrected as described in [38, 20]. For the analysis
of hematopoietic tissues, we took 16 tissues, namely Wholeblood(JJV), CD33
Myeloid, CD14 Monocytes, BDCA4 Dendritic Cells, CD56 NK Cells, CD4
T Cells, CD8 T Cells, CD19 B Cells, CD 105 Endothelial, CD34 Cells, B
Lymphoblasts, Thymus, Tonsil, Lymph node, CD71 Early Erythroid and
Bonemarrow. As representatives for tissues aﬀected by acute and chronic
GVHD we selected liver and skin. The mean mRNA expression level for the
top ranked genes associated with diﬀerent endpoints was compared. Liver and
skin was analyzed separately, whereas mRNA expression of hematopoietic
tissues was both analyzed as the mean of all 16 hematopoietic tissues per
gene, as well as by taking only the highest expressed tissue per gene. The
latter was done, as it is not expected that a gene is highly expressed in all 16
hematopoietic tissues and a potential signal would be lost if a gene is only
highly expressed in one of the hematopoietic tissue types. Observed average
expression and SD for the respective 300 top ranked genes of each list is
shown in Figure 1. A diﬀerence in expression for the diﬀerent endpoints was
expected, we could however not identify any variations in mRNA expression.
An analysis comparing the top 100 ranked genes is reporting similar results.
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Hematopoietic tissues
16 tissues highest expressed Liver Skin
# genes mean SD mean SD mean SD mean SD
m
H
ag
s
relapse decreased 176 6.11 1 6.92 1.35 6.26 1.18 6.18 1.01increased 158 6.06 1.12 6.91 1.49 6.2 1.2 6.13 1.14
acute GVHD decreased 167 5.99 1.02 6.77 1.39 6.12 1.2 6.08 1.06increased 171 6.08 1.05 6.83 1.36 6.32 1.34 6.16 1.08
chronic GVHD decreased 173 6.17 1.07 6.99 1.47 6.27 1.29 6.23 1.09increased 182 6.13 1.1 6.89 1.44 6.18 1.15 6.22 1.16
SN
Ps
relapse decreased 172 6.13 1.07 6.93 1.45 6.28 1.25 6.2 1.1increased 187 6.21 1.25 7.01 1.56 6.24 1.3 6.24 1.21
acute GVHD decreased 169 5.83 1.01 6.52 1.26 5.99 1.18 5.91 1.04increased 168 6.2 1.09 6.88 1.33 6.34 1.24 6.31 1.17
chronic GVHD decreased 179 6.04 1.09 6.91 1.46 6.16 1.32 6.12 1.12increased 191 6.2 1.07 7.05 1.41 6.34 1.16 6.28 1.07
all genes 5542 6.12 1.1 6.92 1.43 6.23 1.23 6.19 1.12
Figure 1. mRNA expression analysis. Tissue expression data is based
on GNF database. The mean expression level for the top 300 ranked genes per
analyzed endpoint is shown. Not all analyzed genes are covered by the GNF
database; the number of analyzed genes in each group is given. Hematopoietic
tissues are listed as a pooled mean over 16 tissues as well as the mean of the
highest expressed tissue per gene. Not all genes part of the study are covered
by the GNF database. The number of genes with expression value is given
by # genes.
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